Epidemiology of healthcare-associated bloodstream infections in the neonatal intensive care unit of Ghent University Hospital by Verstraete, Evelien
Table of content 
 
Summary           2 
Samenvatting           3 
General introduction          5 
  The neonatal population       5 
  General epidemiology       6 
  Infection control practice: theoretical framework    8 
  The NICU of Ghent University Hospital     9 
  Current issues and research questions     10 
  Outline of the thesis        13 
  Publications         13 
Chapter 1  Trends in Healthcare-Associated Bloodstream Infections   16 
Chapter 2 Risk factors for Healthcare-Associated Sepsis    34  
Chapter 3 Impact of Healthcare-Associated Sepsis on Mortality   51 
Chapter 4  Prediction Models for Healthcare-Associated Sepsis: A Meta-Analysis 69 
Chapter 5 Blood culturing Indications: A Multicenter Prospective Cohort Study 96 
Epilogue           117 
List of abbreviations          122 
Reference list           124 







Healthcare-associated bloodstream infection (HABSI) is the most frequent infectious complication in 
critically ill infants admitted to a neonatal intensive care unit (NICU) with substantial risk for neurological 
sequelae and mortality. Therefore, infection prevention initiatives, timely diagnosis, appropriate 
management, and epidemiological research are emphasized. Consequently, the first aim of this research 
was to identify trends in incidence densities and pathogen distribution of HABSIs over a 20-year 
retrospective period in the NICU of Ghent University Hospital; also, risk factors for HABSI and mortality 
were identified. In addition, since timely and accurate diagnosis is crucial and challenging, prediction 
models for HABSI were systematically reviewed. A diagnostic accuracy analysis of prediction models and 
a meta-analysis of the included clinical predictors were performed. Furthermore, a prospective research 
was instigated in the NICU of Ghent University Hospital for validation of our retrospective results. Our 
prospective trail was enlarged by two other NICUs because guidelines on blood culturing indications in 
neonates suspected for HABSI are lacking so various thresholds for sampling are assumed. In this 
multicenter trial, focus was on blood culture sampling practice, ie. sampling frequencies, clinical 
indications, and antimicrobial therapy initiation. Subsequently, a potential sepsis indication model was 
developed and its diagnostic accuracy was calculated.  
We discovered department-specific HABSI patterns and risk factors in our retrospective study. We also 
found substantial difference in sampling practice between the participating NICUs in our prospective 
study. These insights can optimize quality of care concerning HABSI prevention, identification, diagnosis, 
and treatment. Recommendations can be made for (1) monitoring current prevention initiatives for 
compliance, (2) tailoring prevention initiatives towards more appropriate and feasible, and (3) 
standardizing blood culturing indications and antimicrobial therapy initiation. Also, further research 
could validate and improve our developed sepsis indication model and a randomized controlled trial can 




Zorggeassocieerde bloedstroominfectie is de meest voorkomende infectieuze complicatie bij 
pasgeborenen die op een intensieve zorgen afdeling worden opgenomen. Dergelijke infectie kan dodelijk 
zijn of heeft vaak substantiële neurologische gevolgen. Gezien deze erge gevolgen kan er gewezen 
worden op het belang van infectiepreventie, spoedige diagnosestelling en behandeling, en het uitvoeren 
van epidemiologisch onderzoek. De prioritaire doelstelling van dit doctoraatsonderzoek is bijgevolg het 
identificeren van incidentie en de ziektekiemdistributie van de zorggeassocieerde bloedstroominfecties 
die tijdens de periode 1992-2011 zijn voorgekomen in de neonatale intensieve zorgenafdeling van het 
Universitair Ziekenhuis te Gent. Eveneens zal gezocht worden naar risicofactoren voor deze infecties en 
voor mortaliteit. Een volgende doelstelling is het systematisch bestuderen van reeds bestaande 
modellen die een bloedstroominfectie proberen te voorspellen; van deze modellen zal een diagnostische 
accuraatheidsanalyse zal en een meta-analyse van de klinische predictoren worden uitgevoerd. Naast dit 
retrospectieve deel, wordt ook een multicentrisch prospectief onderzoek verricht met de volgende 
doestellingen: (1) validatie van de retrospectieve resultaten; (2) in kaart brengen van indicaties voor 
bloedcultuur afname, afname frequenties en antimicrobiële therapie initiatie in drie verschillende 
neonatale intensieve zorgen afdelingen; (3) een predictiemodel ontwikkelen voor zorggeassocieerde 
bloedstroominfecties en het berekenen van de diagnostische accuraatheid.  
Met het retrospectief onderzoek hebben we patronen en risico factoren kunnen in kaart brengen voor 
de bloedstroominfecties. Via het multicentrisch prospectief onderzoek zijn substantiële verschillen 
geobserveerd betreft bloedcultuur afname beleid tussen de drie participerende centra. De bekomen 
inzichten kunnen leiden tot het optimaliseren van en het ontwikkelen van geschikte infectiepreventie 




Aan de hand van de resultaten van dit onderzoek kunnen volgende aanbevelingen worden gemaakt: (1) 
monitoren van het correct uitvoeren van de geïmplementeerde preventie initiatieven; (2) aanpassen van 
de geïmplementeerde preventie initiatieven betreffende haalbaarheid en geschiktheid; (3) 
standaardisatie van bloedcultuur indicaties en antimicrobiële therapiestart. Vervolgonderzoek zou het 
ontwikkelde predictiemodel kunnen valideren en via een gerandomiseerde studie kan de impact na 

















The neonatal population 
Newborns admitted to a neonatal intensive care unit (NICU) are perceived as critically ill and as such a 
highly vulnerable population. Although all highly vulnerable, they are also deliberated as a miscellaneous 
cohort because of variation in severity of illness mainly related to the level of prematurity and/or low 
birth weight. A neonate is defined as preterm when born alive before the gestational age of 37 weeks; 
following categories are described: extremely preterm (<28 weeks), very preterm (28 to <32 weeks), and 
moderate preterm (32 to <37 weeks). For low birth weight neonates, ie. weighing less than 2500 g, 
following categories are commonly used: extremely low birth weight (<1000 g), very low birth weight 
(VLBW, 1000 to <1500 g), and moderate low birth weight (1500 to <2500 g).1 Although birth weight and 
gestational age are very powerful determinants, other morbidities and comorbidities may have 
additional predictive power when determining severity of illness; mainly severe congenital 
malformations (ie. heart and neural tube defects), intraventricular hemorrhage, and bronchopulmonary 
dysplasia are reported as neonatal (co)morbidities independently determining severity of illness.2, 3  
The past decades advances in medical technologies are remarkable and have resulted in improved 
obstetric and perinatal management and implementation of neonatal intensive care facilities. These 
advances also have led to increased survival of neonates born extremely premature  and/or with a 
complex (congenital) defect.3-6 Mainly the use of surfactant replacement therapy and antenatal 
corticosteroid administration in cases of suspected preterm labor in the first half of the 1990s, have led 
to a remarkable drop in neonatal mortality; 2 large multicenter studies in the United States report an 
absolute decline of respectively 12% (from 53% to 41%) in extremely low birth weight and of 10% (from 
26% to 16%) in VLBW infants.7, 8 Although the crude mortality rate has decreased substantially, mortality 
is still reversely associated with gestational age and/or birth weight.2, 7 In Flanders as well as in other 
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countries, an augmentation of approximately 30% in premature newborns (<37 weeks of gestational age 
or <2500 g birth weight) was observed during the 1980s and 1990s, mostly related to twin or multiple 
gestations and survival of extremely premature newborns.9-12 Subsequently to the persistent medical 
evolution, the edge of viability of those extremely preterm newborns, mostly defined at 25 weeks of 
gestational age, is under discussion implicating a gray-zone between 22 to 24 weeks of gestational age.13, 
14 This discussion is multidimensional: as well medical, social, as ethical aspects needs to be considered, 
though beyond the scope of this thesis.  
Although advanced prenatal care can improve the perinatal health condition of the newborn and 
potentially reduce the severity of illness at time of birth, those newborns admitted to a NICU are 
seriously ill resulting in an advanced need of invasive diagnostic and therapeutic interventions.4, 9, 15 
Therefore, they are at great risk (intrinsic and extrinsic) for healthcare-associated infections. For 
premature neonates, besides this dependency on medical interventions and devices such as catheters or 
ventilators (extrinsic risk factors), their immature immune system with no or limited transfer of maternal 
antibodies before 34th week of gestation, a nonoptimal gastrointestinal flora (exogenous microbial flora 
from endemic microorganisms present in the NICU), and a poor keratinized and highly permeable skin 
and mucous membranes (intrinsic risk factors) make them excessively prone to healthcare-associated 
infections, in particular to healthcare-associated bloodstream infections (HABSI).10, 16, 17 For all of this, 
critically ill newborns are a very important research population. 
General epidemiology of healthcare-associated infections 
Healthcare-associated infections occur after two days of hospital admission and are acquired from the 
caregiving environment. 1 These infections, mainly device-associated such as ventilator-associated 
pneumonia and catheter-related bloodstream infection are unfortunately very common in neonatal 
intensive care. The reported incidence of healthcare-associated infections in NICUs is ranging from 8% to 
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50%.5, 10, 18 In adult intensive care units, it is reported that healthcare-associated infections affect up to 
23% of the patients.19-21 As mentioned earlier, those critically ill newborns are for several reasons 
extremely prone to healthcare-associated infections elucidating these high incidence rates; variance in 
infection control practices, case mix, and length of stay might explain the wide range in incidence. In 
NICUs, the most frequent site of healthcare-associated infection is the bloodstream (up to 75% of all 
infections) which is in approximately 88% of the cases catheter-associated; reported incidence rates of 
ventilator-associated pneumonia are considerably lower  (respectively up to 30% of all healthcare-
associated infections).5, 15, 22-24 Concerning catheter-associated bloodstream infection, 2 possible 
pathways for contamination are reported: intraluminal, ie. by intravenous fluid or the catheter hub, or 
extraluminal, ie. by local skin flora of the healthcare professional or environmental flora. When the 
catheter tip or hub is cultured and colonized with the identical blood culture grown pathogen the 
bloodstream infection is defined as catheter-related.24 In clinical practice, the hub and/or tip are not 
systematically cultured so epidemiology of catheter-associated bloodstream infection is mostly reported. 
During the retrospective study period no data of catheter insertion, -type, or -days were collected; data 
on total parenteral nutrition (TPN) administration and duration was collected. For this, the HABSI rate in 
relation to vascular access is expressed by the number per 1.000 total parenteral nutrition days. 
Subsequently, it was not possible to gain more insight into catheter colonization and to differentiate 
between risk of intravenous lipid emulsion and risk of intravenous access.    
In critically ill newborns, HABSI, also termed healthcare-associated sepsis (HAS), has high incidence rates 
ranging from 5 to 36%; the highest incidence rates are observed for VLBW newborns.5, 8, 10, 25 Besides the 
influence of case mix, the wide range in incidence is also the result of a large variety in case definitions; 
explicitly the current definitions for HABSI caused by a nonrecognized pathogen are ambiguous. In 
neonates, nonrecognized pathogens are generally skin commensals, ie. coagulase-negative 
Staphylococcus spp. and viridans streptococcal spp.10 When a HABSI is caused by one these pathogens, 
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extra criteria are recommended to exclude contamination but the proposed additional criteria are 
dissimilar and not validated.1, 10, 26  
Besides high incidence, HABSI can result in neurodevelopmental deficiency, ie. cerebral palsy, cognitive 
delays, and blindness. Also growth impairment, a rise in mortality rate up to 24%, and additional length 
of stay and hospital charges are reported as a consequence of HABSI.4, 18, 27-29 Therefore, infection 
prevention initiatives, timely diagnosis, and appropriate management of HABSI are emphasized. Previous 
research on prevention initiatives, point out the necessity of good hand hygiene, catheter care, and 
continuous education.30-33 In order to determine an efficient infection control program continuous 
surveillance and epidemiological research is also recommended.4, 34 Concerning risk for HABSI, previous 
epidemiological research revealed that besides the intrinsic risk related to low birth weight (ie. 
underdeveloped immune system, highly permeable skin and mucous membranes, etc.), extrinsic risk 
related to medical interventions such as (prolonged) mechanical ventilation, (prolonged) parenteral 
nutrition administration, catheterization, and surgery are considered independent risk factors.8, 10, 28, 35, 36 
However, because of department-specific policies and specialist services and different levels of care, 
heterogeneity in study population is assumed and recommendations are made for conducting an 
individual epidemiologic research in the search for department-specific pathogen distributions and risk 
factors in order to determine an appropriate infection control practice.9, 37  
Infection control practice: theoretical framework 
The term healthcare-associated is preferred in this thesis instead of nosocomial as proposed by the 
Centers for Disease Control and Prevention, because it adds to clarity: healthcare-associated clearly 
implies that healthcare providers and environment are involved. The Center for Disease Control and 
Prevention and other national societies developed evidence-graded guidelines for the prevention of 
device-associated and/or healthcare-associated  infections; hand hygiene, full-barrier precautions during 
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insertion, disinfectant time and preparation, procedures for device care and dressing change, education 
of staff, checklists with procedure indicators and with indicators for device removal, ongoing 
surveillance, are evidence-based infection prevention initiatives.38, 39 Research on the effect of bundled 
prevention initiatives do point out the boosted effect of care bundles and highlight our responsibility as 
healthcare professionals: it is estimated that approximately 80% of all healthcare-associated infections in 
(neonatal) intensive care are evitable.40-43 One prospective cohort study conducted in an surgical adult 
intensive care unit showed that a multifaceted approach helped to reduce/eliminate catheter-related 
bloodstream infections (from 11.3/1.000 to 0/1.000 catheter days).20  
For now, a decrease in VLBW newborns is not expected, so intrinsic risk for healthcare-associated 
infections remains high as well as all intrinsic-associated extrinsic risk factors. Nevertheless, it is our duty 
to strive for zero healthcare-associated infections and for this we need to continuously improve quality 
of care by implementing the most recent evidence based infection prevention initiatives and tailoring 
those initiatives towards the results of a department-specific epidemiological research. In addition, 
healthcare providers need to ensure adherence to those tailored infection prevention initiatives; all 
together we can do this!  
The NICU of Ghent University Hospital 
Ghent University Hospital is a teaching hospital and tertiary referral center with a 32-bed maternity 
ward, including 8 maternal intensive care beds, and a 32-bed NICU. Of the circa 1200 deliveries per year, 
approximately 230 newborns (19%) are transferred to the NICU. Only newborns less than 28 days of life 
are admitted to this unit. The yearly mean admission rate over the past 20 years was 492 of which 54% 
were outborn, ie. transferred after birth. Of the total yearly admissions approximately 100 were VLBW 
infants, ie. weighing 1500 g or less. Neonatal specialist services include pediatric cardiology and cardiac 
surgery with on average 70 cases per year; 50 need surgery during the neonatal period.  
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Since 1992, Ghent University Hospital is participating in a national surveillance program on infections in 
Belgian hospitals. The hospital hygiene team is responsible for collecting the predefined clinical and 
microbiological data in a standardized way; till 2001 the data was collected through nonelectronic 
registration forms and since 2002 an electronic submission system was available and a central database 
was generated. This database and the nonelectronic registration forms were used for patient 
identification in this doctoral research. In addition, medical files of all included cases were reviewed by 
the doctoral researcher to determine the diagnostic certainty of the infection; since 2002, an electronic 
department-specific audit system (NICAUDIT) was available for reviewing medical data. The database of 
the NICAUDIT uses predefined variables including neonatal and maternal demographical data, neonatal 
and maternal (co)morbidities, neonatal treatment procedures, and neonatal discharge modus and 
status. This database is completed by the neonatal medical staff. The research population and variables 
of this research is based on all these standardized surveillance systems.   
Besides surveillance of infection, no official infection control initiatives were implemented in the NICU of 
Ghent University Hospital; the norm ‘good practice’ was the standard. A protocol for catheter care was 
implemented in 2006 according to the 2002 guidelines of the Centers for Disease Control and 
Prevention.  
During the study period there was a progressive increase in nursing and medical staff in the NICU of 
Ghent University Hospital  in accordance with the population increase. 
Current issues and research questions 
As stated earlier, considering the burden of HABSI, prevention, surveillance and the need for an 
unambiguous case definition, early diagnosis, appropriate management, and department-specific 
epidemiologic research are emphasized.  
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Regarding the department-specific epidemiologic research in the NICU of Ghent University Hospital, the 
first research questions are:  
1. What is the incidence of HABSI and their causative pathogens during a 20-year period (1992-
2011)?; is there a trend to discern in incidence or in pathogen distribution?;  
2. What are the department-specific adjusted and unadjusted risk factors for HABSI?;  
3. What are the department-specific adjusted and unadjusted risk factors for mortality in neonates 
with and without HABSI? 
Despite well-conducted previous research, several issues concerning correct and timely diagnosis, and 
management of HABSI do persist. Extensive research has been done on single laboratory tests or a 
combination of tests in bloodstream infection diagnosis unfortunately with conflicting results. 
Nevertheless, blood culture is the gold standard test to diagnosis bloodstream infection but prone to 
false-negative or false-positive results. In particular blood cultures positive for skin commensals, mainly 
coagulase-negative staphylococci, are common and problematic in the newborn because they may 
represent either true infection or contamination. Blood culture sampling in neonates, especially in low 
birth weight neonates, is a challenging procedure so contamination is likely and for this, as mentioned 
above, extra criteria are warranted. On the other hand, low blood culture volumes or antimicrobial 
therapy before blood cultures were drawn might represent false-negative results.44-46  Furthermore, the 
blood culture test is not only imprecise but also time-consuming; a pathogen detection time of at least 
12 hours plus additional time for microbial assays is required. In addition to these diagnostic issues of 
correct and timely diagnosis, management of HABSI is also a major concern. Hence both in respect to 
diagnostic and management strategy, clinicians have to make preliminary decisions often based on 
largely nonspecific signs, particularly in VLBW neonates. Because of the possible devastating 
consequences of HABSI, a low threshold for initiating empiric antimicrobial therapy is generally 
accepted.47-49 Nonetheless, inadequate, inappropriate, or unnecessary empiric treatment can foster 
12 
 
antimicrobial resistance, compromise gastrointestinal immunity and be associated with adverse 
outcomes.50-52 Considering these diagnostic and therapeutic issues, prediction models with clinical 
parameters, in particular clinical signs and risk factors, are developed to facilitate preliminary sepsis 
diagnosis and the initiation of antimicrobial therapy. For this, the next research questions are:  
4. How many prediction models for HABSI in hospitalized neonates are developed and what is their 
content and diagnostic accuracy?;  
5. Which clinical parameters are superior in the prediction of HABSI?  
For the validation of our retrospective results and for the investigation of blood culture sampling 
indications, a prospective research was started up in the NICU of Ghent University Hospital. Incidence of 
lab-confirmed and clinical sepsis, risk factors, and clinical indications including ten predefined clinical 
signs, were registered at time of blood culturing. Moreover, because guidelines on blood culturing 
indications in neonates suspected for HABSI are lacking, various thresholds for sampling are assumed 
and for this, the prospective trail was enlarged by 2 other NICUs. In this multicenter trial focus was on 
blood culture sampling practice which addresses following research questions:  
6. What are the sampling frequencies?;  
7. What are the clinical indications for sampling?;  
8. When is antimicrobial therapy initiated?;  
9. When is antimicrobial therapy administered for 5 days or more?; 
10. Is there any difference between centers concerning sampling practice?  
Finally, because of the hypothesis that guidance in blood culture sampling might lead to a more efficient 
sampling practice and because of the limited diagnostic accuracy of the current developed prediction 
models, a potential sepsis indication model was developed. The last research questions was: 
11. What is the diagnostic accuracy of the sepsis indication model?  
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Outline of the thesis 
The primary purpose of this research was to identify trends in incidence densities and pathogen 
distribution of HABSIs over a 20-year period in the NICU of Ghent University Hospital in order to clearly 
define baseline data allowing follow-up of prevention initiatives (Chapter 1). Also, risk factors for HABSI 
and mortality in critically ill infants of Ghent University Hospital were identified so current prevention 
initiatives can be improved appropriately (Chapter 2-3). In addition, since timely and accurate diagnosis 
of HABSI is crucial and challenging because of a time-consuming and imprecise blood culture test, 
prediction models were the topic of interest in the subsequent part of this research. In Chapter 4, 
prediction models for HABSI were systematically reviewed. Also, a diagnostic accuracy analysis of the 
prediction models and a meta-analysis of the included clinical predictors were performed. Furthermore, 
for validation of our retrospective results and for the examination of blood culture sampling practice, a 
prospective multicenter research was instigated. The results of this prospective study concerning 
sampling frequencies, clinical indications for sampling, antimicrobial therapy initiation, and the 
development and diagnostic performance of a sepsis indication model, are described and discussed in 
Chapter 5. 
Publications included in the thesis: A1 and Q1 
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Impact factor: 3.9 
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The primary purpose of this research was to identify trends in incidence densities and pathogen 
distribution of HABSIs over a 20-year period in the NICU of Ghent University Hospital in order to clearly 
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Objectives: To analyze trends in the incidence and pathogen distribution of healthcare-associated 
bloodstream infections (HABSIs) over a 20-year period (1992-2011).   
Design: Historical cohort study 
Setting: Thirty-two-bed neonatal intensive care unit (NICU) in a tertiary referral hospital.  
Patients: Neonates with HABSIs defined according to the criteria of the National Institute of Child Health 
and Development (NICHD).  
Methods: A hospital-based ongoing surveillance program was used to identify HABSI cases in neonates. 
A distinction between definite or possible HABSI was made according to the NICHD criteria. Incidence, 
incidence densities (HABSIs per 1,000 hospital days and HABSIs per 1,000 TPN-days), and case fatality 
rate were calculated. Logistic regression analysis was used to find time trends. Four periods of 5 years 
were considered when executing variance analysis.  
Results: In total, 682 episodes of HABSIs occurred on 9,934 admissions (6.9%). The median total 
incidence density rate was 3.1 (interquartile range, 2.2-3.9). A significant increasing time trend in 
incidence density was observed for the period 1995-2011 (P<.003). A significant decrease in case fatality 
rate was found in the last 5-year period (P<.001). No neonate died following possible HABSIs, whereas 
the case fatality rate among neonates with definite HABSIs was 9.7%. Most HABSIs were caused by 
coagulase-negative staphylococci (n = 414, 60.7%). A significant increase in Staphylococcus aureus HABSI 
was observed in the last 10-year period (P<.001).  
Conclusion: An increase in incidence density rate occurred, while the case fatality rate dropped.  Better 
perinatal care could be responsible for the latter. A decrease in days before infection and a high 
incidence of coagulase-negative Staphylococcus HABSIs, indicates the need for vigorous application of 










Healthcare-associated bloodstream infection (HABSI), is a frequent complication in neonatal intensive 
care units (NICUs). Previous studies document incidence rates ranging from 5% to 32%.1, 10, 37 Risk factors 
for HABSI include lower birth weight, lower gestational age, prolonged mechanical ventilation (MV), 
parenteral nutrition and vascular access.10, 36, 53 For neonates with very low birth weight (VLBW, ≤1,500 
g), the National Institute for Child Health and Human Development (NICHD) reported an incidence of 
21%.10 HABSIs result in longer hospitalization (plus  23 days, on average) and a rise in mortality rate up to 
24% for VLBW neonates.8-10, 18, 27, 28  
The past decade’s further implementation of neonatal intensive care facilities has led to increasing 
survival rates among preterm neonates.15, 54 Neonates are younger gestational age and lower birth 
weight, and because of this they might be more seriously ill. Therefore, they may be more susceptible to 
HABSIs.10 Conversely, implementation of new knowledge by means of care bundles and infection control 
practices might stabilize or alter the possible increasing direction.40, 55 
The purpose of this study was to identify trends in incidence densities and pathogen distribution of 
HABSIs over a long period (20-years, from 1992 through 2011) in a tertiary NICU setting to clearly define 
baseline data, allowing follow-up of prevention initiatives.  
METHODS 
Study design  
We performed a single-center historical cohort study considering all neonates admitted during a 20-year 
period (1992-2011) whose NICU stay was complicated by at least one HABSI. Files of all included cases 
were reviewed to determine the diagnostic certainty of the infection. 
The study was approved by the Ethics Committee of Ghent University Hospital.  
Setting and patients 
Ghent University Hospital is a teaching hospital and tertiary referral center with a 32-bed NICU. Only 
newborn infants (ie, less than 28 days of life) are admitted to this unit. The yearly mean admission rate 
over the past 20 years was 492 (range 403-593) with approximately 100 (range 95-115) VLBW infants. 
Neonatal specialist services include pediatric cardiology and cardiac surgery with, on average, 70 cases 
per year, of whom 50 need surgery during the neonatal period. During the study period there was a 
progressive increase in nursing and medical staff, in accordance with the population increase. 
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Infection control practices 
Besides surveillance, no official infection control program was implemented before 2006. The norm 
‘good practice’ was the standard. Hand hygiene standards did not change over time but were more 
visible since 2006; posters on hand hygiene were found next to all sanitary locations. Catheter dressings 
changed in July 1994 from non-permeable to high-permeable polyurethane dressing. A protocol for 
catheter care was implemented in 2006 according to the 2002 guidelines of the Centers for Disease 
Control and Prevention (CDC).38 
Case-finding  
Since 1992, laboratory-based surveillance of positive blood culture results has been performed by the 
infection control team. Clinical significance, mode of transmission (ie, congenital, vertically transmitted 
[mother-to-infant], healthcare-associated or community acquired) and source of infection were 
determined.  
The cohort is based on this ongoing surveillance program. Since 2002, a NICAUDIT electronic database 
system was used in order to identify additional HABSI cases and to collect demographic and outcome 
data. For the present study, following conditions were collected: MV, total parenteral nutrition (TPN), 
major surgery. 
Definitions  
Healthcare-associated infection (HAI) is defined according to the CDC/National Healthcare Safety 
Network (NHSN) criteria published in 2008.1 A neonatal HAI is considered healthcare-associated when it 
is not transplacentally transmitted, occurring more than  48 hours after birth, and not a reactivation of a 
latent infection caused by, for example, Herpes zoster, Herpes simplex, syphilis, or tuberculosis. To define 
the diagnostic certainty of a laboratory-confirmed bloodstream infection in patients less than or equal to 
1 year of age, the following adapted CDC/NSHN criteria were considered : (1) distinction between skin 
contaminant and recognized pathogens (Table 1) and (2) the blood-cultured pathogen could not be 
related to another infection site.  





Table 1. Definite,  Possible, and Probable Healthcare-Associated Bloodstream Infection (HABSI) According to the Criteria of the National 
Institute of Child Health and Development.  
 
Blood culture results considered as probable HABSI are not included in our cohort. A HABSI episode is 
defined new if the same organism was cultured after 10 days of appropriate antibiotic therapy or if a 
different organism was cultured from a subsequent culture.10 
Case fatality rate is the percentage of HABSI cases whose death is related to the HABSI, on the basis of 
clinical judgment.  
TPN is the intravenous administration of an admixture of at least 2 major nutritional components (ie, 
carbohydrate and amino acids or lipids). 
Blood culture sampling and processing  
Blood cultures were obtained through an arterial central line or by peripheral puncture. There were no 
changes in blood culture sampling policy and no significant changes in the total number of blood cultures 
taken yearly during the last 10 years of the study period (mean 492, range 449-555). Blood cultures were 
assessed using the Bactec-system (Becton Dickinson Microbiology System) until 1995 and the BacT/Alert 
3D automated microbial detection system (bioMérieux) since 1996. 
Occurrence rates 
Incidence is defined as the number of HABSIs per 100 neonates during the 20-year study period.          
HABSI Pathogen Number of positive  
blood cultures 
Other criteria 
Definite  Recognized ie. S. aureus, Enterococcus 
spp., E. coli, Pseudomonas spp., 
Klebsiella spp., Candida spp., and 
others 
1 None 
 Possible/Skin contaminant ie.  
Corynebacterium  spp., Bacillus (not B. 
anthracis) spp., Propionibacterium 
spp., CoNS spp., viridans group 
streptococci, Aerococcus spp., and 
Micrococcus spp. 
2  Blood drawn within 48h of each other 
(separate occasions) and having grown the 
same possible pathogen 
Possible  Possible/Skin contaminant 1  C-reactive protein > 1 mg/dl 
Anti-staphylococcal agent for ≥ 5 days 
Probable  Possible/Skin contaminant  1  Does not meet criteria ‘possible’ 
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Incidence density is defined as the number of HABSIs per 1,000 hospital days, calculated for total, 
definite, and possible HABSIs. 
The HABSI rate in relation to vascular access is expressed by number per 1,000 TPN-days (ie, total TPN-
days.                                                                                                                                          
Statistics 
Variables are described as number (%) or median (interquartile range). Comparisons between groups 
were performed using Mann-Whitney U test (2 groups) or Kruskal-Wallis test  (more than 2 groups) for 
continuous variables and the chi-squared test for categorical variables. Four consecutive periods of 5 
years were considered:  period 1 (1992-1996), period 2 (1997-2001), period 3 (2002-2006), and period 4 
(2007-2011). Logistic regression analysis was used to evaluate the time trend in incidence densities 
during the 20-year study period. SPSS, version 21, was used for all tests. 
RESULTS 
Trends in occurrence rates 
During the study period 9,829 neonates were admitted to the NICU, and 682 HABSI episodes were found 
in 620 HABSI cases. Respectively 444 (65%) and 238 (35%) were definite and possible HABSIs. Fifty-three 
of 620 HABSI cases (8.5%) developed a second episode, and 9 (1.5%) of 620 patients experienced a third 
episode. Characteristics, incidence, and incidence densities (total, definite and possible) per period are 
tabulated in Table 2. Over the study period the average yearly incidence was 6.9 per 100 patients and 
ranged from 2.2 (1994) to 13.4 (1992). Total, definite, and possible incidence densities are illustrated per 
year since no subtleties per quartile were observed (Figure 1).  The average total incidence density rate 
per year was 3.1 per 1,000 hospital days (range, 0.9-5.3).  
During the study period, no overall significant trend was observed in total, definite, and possible 
incidence density rates (P=.233; P=.544; P=.765, respectively). Because of the substantial decline 
observed in definite and possible incidence density rate in 1994, a secondary logistic regression analysis 
was performed for the period 1995-2011. This analysis revealed a significant increasing trend in total and 
definite incidence density rate (P=.003 and P=.020, respectively). Variance analysis showed that 
distribution of the total and possible incidence density rate revealed no difference across the 4 periods 
(Table 2). In contrast, a difference was found in the distribution of the definite incidence density rate 
(P=.040). Furthermore, a decrease was observed in days before infection (P=.004). For periods 3 (2002-
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2006) and 4 (2007-2011), incidence per 1,000 TPN-days was respectively 7.5 (6.8-9.1) and 8.1 (7.8-9.6) 
(P=.222). HABSI incidence was higher in particular subgroups (ie, VLBW, very low gestational age, TPN, 
and MV; table 2).  
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Table 2. Epidemiological Features and Incidence Densities of Healthcare-Associated Bloodstream Infections for the Four 5-Year Periods.   











Total patients, no. 9,829 2,154 2,346 2,469 2,860  
Total hospital days, no. 131,332 52,010 52,110 56,209 55,992 .095 
HABSI episodes, no. (%) 682 170 (7.9) 117 (4.9) 183 (7.4) 212 (7.4) .042 
HABSI cases, no. (%) 620 165 (7.7) 111 (4.7) 158 (6.4) 186 (6.5) .065 
Proportion definite HABSI,  % 63 56 66 74 69 .052 
Incidence, cases  per 1,000 hospital days   
 Total HABSI, median (IQR) 












 Definite HABSI, median (IQR) 












 Possible HABSI, median (IQR) 












No. per 1,000 TPN-days, median (IQR) 
No. per 1,000 TPN-days, mean (range) 





Total patients with TPN, no. (days) 
   HABSI-cases with TPN, no. (days) 
   HABSI-cases per non-TPN patients, % 









Total TPN, days, median (IQR) 
Total TPN, days, mean (range) 





GA, weeks, median (IQR) 
GA, weeks, mean (range) 
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VLGA (≤31weeks), % 
  HABSI cases per VLGA patients, % 










Birth weight, gram, median (IQR) 
Birth weight, gram, mean (range) 





VLBW (≤1,500 gram), % 
  HABSI cases per VLBW patients, % 
  HABSI cases per non-VLBW patients, % 









Sex, male, %    60 54 .391 
Length of stay, days, median (IQR) 
Length of stay, days, mean (range) 





Total patients with MV, no. (days) 
   HABSI cases with MV, no. (days) 
   HABSI cases per non-MV patients, % 









Duration of MV, days, median(IQR) 
Duration of MV, days, mean (range) 





Days before infection, median (IQR) 
Days before infection, mean (range) 





Inborn, % (proportion IUT, %)    46 (70) 48 (77) .777 
Major surgery, %    29 42 .055 
Case fatality rate, no. (%) 38 (6.1) 12 (7.2) 10 (8.9) 12 (7.5) 4 (2.1) <.001 
NOTE. ‘Days before infection’ are the days since birth till infection; GA, gestational age; HABSI, healthcare-associated bloodstream infection;  IQR, interquartile range; IUT, intrauterine transfer; MV, 














Trends in pathogen distribution  
The 682 HABSIs were caused by 717 pathogens, of which 80.2%, 18.7%, 1.1% were gram-positive 
pathogens, gram-negative pathogens, and fungi, respectively (Table 3). Slightly more than 5% (n=35) of 
the HABSIs were caused by 2 pathogens.  In 19 polymicrobial HABSIs (54.3%) coagulase-negative 
staphylococci (CoNS) were involved of which 17 occurred in the second 10-year period (2002-2011). 
Eleven (31.4%) blood cultures revealed mixed growth with Enterococcus spp. of which 6 included CoNS. 
In the first (1992-2001) and the second (2002-2011) 10-year period, respectively, 7 (70%) of 10 and 5 
(20%) of 25 polymicrobial HABSIs involved a gram-negative pathogen. Of the 53 second-episode HABSIs, 
28 were caused by the same pathogen of which 19 (67.9%) were CoNS, and 25 episodes were caused by 
two different pathogens. Pathogen distribution, divided in two 10-year study periods, is shown in Table 
3. The most common causative pathogens were CoNS accounting for 60.7% of all HABSIs. Of these CoNS 
HABSIs, 183 (44%) were definite and 231 (56%) were possible HABSIs. The most common ‘recognized’ 
pathogens were Enterobacteriaceae (16.0%), Staphylococcus aureus (11.1%), and enterococci (6.2%). 
Pseudomonas spp. (2.5%) and Candida (1.2%) were rare.  Six S. aureus isolates (7.9%) were methicillin 
resistant.  
Incidence per 1,000 hospital days of the 4 most common pathogens are displayed in Figure 2. CoNS 
remained the main pathogen during the whole study period. As for enterococci, S. aureus, and 
Enterobacteriaceae no time trend was detected. In contrast, variance analysis revealed an increase in S. 
aureus HABSI (P<.001) comparing the periods 1992-2001 and 2002-2011. A peak in S. aureus HABSI was 
found in 2005 (n=9; 1.13 per 1,000 hospital days) of which 4 were methicillin resistant. 
Two clusters (more than or equal to 3 HABSI of same pathogen per week) were detected. In October 
1993, 4 Pseudomonas aeruginosa HABSIs occurred within 3 days and in June 2005, 3 MRSA HABSIs 








Table 3. Frequencies and Associated Mortality of the Main Gram-Positive and Gram-Negative Pathogens.  







mortality   
 
Total pathogens, n (%) 717 (100) 299 (41.7) 418 (58.3) 40 (5.6) 
CoNS, n (%) 414 (57.7) 186 (62.2) 228 (54.5) 3 (7.5) 
S. aureus, n (%) 76 (10.6) 17 (5.7) 59 (14.1) 3 (7.5) 
Enterococcus spp., n (%) 42 (5.9) 15 (5.0) 27 (6.5) 0 
Other GPP, n (%) 43 (6.0) 11 (3.7) 32 (7.7) 0 
E. coli, n (%) 35 (4.9) 14 (4.7) 21 (5.0) 8 (20.0) 
Enterobacter spp., n (%) 46 (6.4) 24 (8.0) 22 (5.3) 14 (35.0) 
Klebsiella spp., n (%) 22 (3.1) 10 (3.3) 12 (2.9) 4 (10.0) 
Pseudomonas spp., n (%) 17 (2.4) 14 (4.7) 3 (0.7) 4 (10.0) 
Other GNP, n (%) 14 (2.0) 7 (2.3) 7 (1.7) 3 (7.5) 
Candida spp., n (%) 8 (1.1) 1 (0.3) 7 (1.7) 1 (2.5) 
Total GPP, n (%) 575 (80.2) 229 (76.6) 346 (82.8) 6 (15.0) 
Total GNP, n (%) 134 (18.7) 69 (23.1) 65 (15.6) 33 (82.5) 
Polymicrobial HABSIs, n 35 10 25 2 
CoNS, coagulase-negative Staphylococcus; GNP, gram-negative pathogen; GPP, gram-positive pathogen; HABSI, healthcare-associated 
bloodstream infection 
Outcomes associated with HABSIs 
Thirty-eight of 620 HABSI cases died because of HABSI (6,1%, case fatality rate). No neonates of the 
entire possible HABSI group (n=229) died because of a HABSI, so deaths occurred in the definite HABSI 
group (n=391; 9.7% case fatality rate). Considering the 4 periods, a significant decrease in case fatality 
rate was found (P<.001). 
No significant difference was found between 2002-2006 and 2007-2011 in case fatality rate for VLBW 
patients versus non-VLBW patients and for surgical patients versus non-surgical patients (data not 
shown). 
The causative pathogens and their association with mortality are tabulated in Table 3. In the group with 
polymicrobial HABSIs 2 neonates died (2/35, 5.7%) which was not different from the monomicrobial 





Figure 2. Number of healthcare-associated bloodstream infections (HABSIs) caused by coagulase-negative Staphylococcus (CoNS), S. aureus, Enterococci,  





We reviewed trends in incidence density of HABSIs in a tertiary NICU setting over a 20-year period. A 
statistically significant increase in total and definite incidence density rate was found during the period 
1995-2011. A relative increase of S. aureus HABSI was observed in the last 10 years. No further changes 
in pathogen distribution occurred. The case fatality rate significantly decreased in the last 5 years.  
Trends in occurrence rates 
An incidence of 6.9 per 100 neonates and an incidence density rate of  3.1 per 1,000 hospital days, 
indicate that HABSIs remain an important issue in our NICU. Because of a large variety of case 
definitions, a wide range in incidence and incidence density rates was observed when reviewing 
literature, thereby hampering benchmarking. Future research should consider the use of a uniform case 
definition for the surveillance of HABSI, such as the one developed by Modi et al.56 Additionally, NICU 
departments should participate in an (inter)national surveillance network to facilitate benchmarking.  
During the entire study period, fluctuations in incidence densities were observed, but no overall trend in 
total HABSI incidence density was found (1992-2011). In contrast, an increasing trend was found for the 
period 1995-2011. This secondary logistic regression analysis was made to exclude the 2 extreme 
incidence density values, that is, 5.3 (1992) and 0.9 (1994). In 1994, a randomized controlled trial of 
catheter care was conducted. During the 6 months of intervention, the overall HABSI rate dropped 
tremendously. The investigators assumed that a Hawthorne effect caused this favorable decline 
(Lemaitre D, MSc; Master thesis Ghent University, June 1995). Similar effects are described when starting 
up surveillance of HABSIs.34, 40 Strict adherence to the study protocol might be another explanation for 
the observed decline. Before 1994, we may assume that no attention was paid to HABSIs which might be 
responsible for the higher incidence density rates in 1992-1993.  
Variance analysis revealed an increase across the 4 periods for the definite incidence density  rate. 
Increasing survival rates of the preterm newborns during the last decades could be associated with this 
finding. 
It is acknowledged that the criteria of the NICHD may overestimate true rates of CoNS-HABSIs.10 In this 
study no distinction was made between the different CoNS (S. epidermidis, S. hominis etc.) so an 
overestimation of the category of definite CoNs HABSIs is likely. However, classification as definite or 
possible was made retrospectively and the 2 backup systems (ie, medical files and NICAUDIT) were 
available only since 2002. Considering these factors, misclassification before 2002 is plausible, skewing 
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classification towards possible CoNS HABSIs. Nevertheless, only laboratory-confirmed HABSIs are 
included in this cohort, favoring underestimation of the true HABSI rate. 
TPN-days were used to express incidence in relation to vascular access, since the number of total 
catheter-days was not available. Consequently, an overestimation of the HABSI rate in relation to 
vascular access is likely. The denominator TPN-days has already been proposed as a higher standard than 
catheter-days, and, although not an apt proxy, it may be more appropriate in defining days at risk.36, 57 In 
our cohort, we observed that almost all HABSI cases of period 3+4 received TPN (n=331/344, 96.2%) and 
MV (n=231/344, 67%). For both devices and for the two periods, a significant difference was found in the 
proportion HABSI cases per device versus HABSI cases per nondevice. This observation might confirm 
that TPN and MV are major risk factors. Note that MV may be instituted after HABSI, so MV statistics 
could be biased.  
We could not discern any changes in characteristics of the HABSI cohort. It should be considered that 
data were missing for the period 1992-2001. However, for the period 2002-2011 there was a decrease in 
days before infection; in particular the lower quartile was halved. On the basis of observations made in 
an adult ICU, Zingg et al.58 hypothesized that faster occurrence of infection might imply issues with 
catheter care, that is, adherence to or adoption of insertion bundles.58 This can also be valid for a NICU-
setting. Another NICU study of Zingg et al.59, showed that catheter indwelling time is a risk factor for 
HABSI and clinical sepsis, so time to infection should be placed in a context of exposure and type of 
catheter.59  
Trends in pathogen distribution 
HABSIs caused by CoNS, Enterococcus spp., and Enterobacteriaceae remained stable during the study 
period. Only for S. aureus an increase was observed. In 2005 an MRSA outbreak  occurred which could be 
responsible for the S. aureus HABSI increase. Nevertheless, the incidence of S. aureus HABSIs remained 
low: 17 of 5449 admissions (0.3%) in the first 10-year period versus 59 of 4380 admissions (1.3%) in the 
last decade. The National Nosocomial Infections Surveillance System (NNIS) reported an increase of 13% 
in healthcare-associated S. aureus infections among all birth weight categories and a 308% increase in 
healthcare-associated MRSA infections (31% bloodstream infections) during 1995-2004.60 As in our 
research, the S. aureus-HABSI  increase was more pronounced since 2002. However, besides the MRSA 




As in other studies, CoNS  are the most common causative pathogens for HABSIs in our NICU.10, 25, 37, 62-65 
The relationship between CoNS HABSIs and vascular access is well known. Therefore, prevention 
strategies need to be directed at improving hand hygiene, skin-disinfection procedures, and so on. Every 
blood culture positive for CoNS should raise suspicion of contamination. It is recognized that surveillance 
according to the NICHD criteria tends to overestimate the HABSI rate, particularly the CoNS HABSI rate. 
To distinguish between contamination and true infection with a skin commensal, more criteria are 
needed. Such criteria are proposed by Modi et al.56. Three on 10 predefined clinical signs could be 
predictive for a positive blood culture (AUC=0,83). This validated model is a nonambiguous case 
definition, is practicable for clinicians, and may be more achievable for the neonate, because no second 
blood culture is required. This model will be used and tested for reliability in our future research. 
An estimation of the contaminated blood cultures might be demonstrated by the number of mixed 
cultures with CoNS or even with Enterococcus spp.66-68 Although enterococci are defined as recognized 
pathogens according to the CDC, Freeman et al.66 are attending to the possibility that enterococci, in 
adults, could be contaminants particularly when mixed with skin organisms. In our cohort, 19 of 35 
mixed cultures included CoNS and 11 included Enterococcus spp. of which 6 also included CoNS. 
Additionally, almost all mixed cultures with CoNS appeared in the second decade. These numbers might 
reflect a high number of contamination and indicate the actual need for training programs on proper 
sampling techniques.55, 69 
Trends in outcome 
A mean 6% case fatality rate reflects the importance of HABSIs as a potential lethal complication in 
NICUs. However, case fatality remains low compared to other studies.9, 10, 28 Similar findings were 
observed concerning the causative pathogens.9, 10 To our knowledge, no study separately reported 
definite and possible HABSI incidence densities and outcome using identical NICHD criteria. One recent 
study by Jean-Baptiste et al.70 on neonatal CoNS infections reported definite and possible rates but used 
different case definitions and did not report mortality of CoNS HABSIs separately.70 Due to our separate 
analysis, we may discern the importance of the definite and possible group: the absence of mortality in 







During the period 1995-2011 an increase in incidence density rate occurred, while a decrease in case 
fatality was noticed during the last decade. Better perinatal care might be responsible for the latter. An 
incidence density of 3.1 per 1,000 hospital days on average, a decrease in days before infection, and a 
high incidence of CoNS as causative pathogen, indicate that HABSIs remain an epidemiological, 
diagnostic, and therapeutic issue in our NICU and stresses the need for vigorous application of evidence-
based prevention measures in particular on catheter care. Our research provides baseline data allowing 
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Background. Health care-associated bloodstream infection (HABSI) is a frequent complication in 
neonatal intensive care. Research on risk factors stratified by birth weight and adjusted for severity of 
illness and comorbidities is limited. Our objective is to describe independent risk factors for HABSI in 
critically ill neonates with emphasis on risk variation between birth weight groups.   
Methods. We performed a single-center historical cohort study in a tertiary referral center. A neonatal 
intensive care-audit system was used to identify eligible neonates admitted for ≥72 hours (2002-2011). 
HABSI is defined according to National Institute of Child Health and Human Development criteria. Risk 
factors for HABSI were assessed by univariate and logistic regression analysis for the total cohort and for 
birth weight subgroups, that is, neonates ≤1500 g and >1500 g.   
Results. A total of 342 neonates developed HABSI in 5134 admissions of ≥72 hours (6.7%). ‘Very low 
birth weight’, ‘total parenteral nutrition’ (TPN), ‘mechanical ventilation’, ‘gastrointestinal disease’, 
‘surgery’ (cardiac and other type), and ‘renal insufficiency’ are independent risk factors for the total 
cohort. ‘Gastrointestinal disease’ and ‘cardiac surgery’ are independent risk factors in both birth weight 
groups; ‘mechanical ventilation’ (adjusted odds ratio [aOR] 2.6, confidence interval [CI] 1.6-4.0) and 
‘other type of surgery’ (aOR 4.3, CI 2.1-8.8) are solely independent risk factors in the ≤1500-g cohort; 
‘TPN’ is exclusively an independent risk factor (aOR 7.9, CI 3.9-16.2) in the > 1500-g cohort.  
Conclusion. In our neonatal intensive care unit, risk stratification by birth weight revealed some 
difference. Special attention concerning infection control practices is for neonates receiving TPN, 











Healthcare-associated bloodstream infection (HABSI) is a frequent complication in neonatal intensive 
care units (NICUs). Previous studies document incidence rates ranging from 5% to 32%.8, 10, 25, 71 For 
neonates with very low birth weight (≤1500g), the National Institute of Child Health and Human 
Development (NICHD) reported an incidence of 21%.10 Likewise, for pediatric and adult intensive care 
patients, HABSI is a common infectious complication.19, 37, 72 Although implementation of new knowledge 
by means of infection control practices might decrease incidence, HABSI remains a leading cause of 
morbidity and mortality. HABSI can result in neurodevelopmental impairment, growth impairment, 
longer hospitalization (on average +23 days), and a rise in mortality rate up to 24% for very low birth 
weight neonates.15, 18, 27, 28, 37  
Although previous studies8, 28, 35, 73-75 searched for risk factors for HABSI in very low birth weight 
neonates, studies on independent risk factors for HABSI are limited in neonates >1500g admitted to an 
academic NICU for surgery or other (sub)specialty care. However, preceding research in academic NICUs 
demonstrated substantial incidence (densities) for neonates weighing >1500g.71, 76 In addition, previous 
research on independent risk factors for HABSI used limited confounding variables. We aimed to 
describe risk factors for HABSI in neonates for a total cohort and for neonates weighing ≤1500 g or >1500 
g  adjusted for initial severity of illness and several underlying comorbidities.  
METHODS 
Study design  
We performed a single-center historical cohort study including all neonates who survived the first 72 
hours after birth and were admitted to our NICU during a 10-year period (2002-2011); for outborn 
infants, admission for ≥72 hours was also required. A NICAUDIT database was used to identify all eligible 
neonates. This database includes neonatal demographical data, comorbidities, treatment procedures, 
and the Clinical Risk Index for Babies (CRIB) score. The CRIB score, solely validated in neonates ≤31 weeks 
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of gestational age, evaluates the severity of illness and the risk for mortality by calculating the sum of six 
parameters (ie, birth weight, gestational age, minimum FiO2, maximum FiO2, congenital malformation, 
and maximum base excess) during the first 12 hours of life.77  
The study was approved by the Ethics Committee of Ghent University Hospital.  
Setting and patients 
Ghent University Hospital is a teaching hospital and tertiary referral center with a 32-bed NICU and a 
birth center with approximately 1200 births per year. Only newborn infants (ie., less than 28 days of life) 
are admitted to this unit. The yearly mean admission rate over the past 10 years was 533 (range 447-
593) of which approximately 18% were neonates weighing 1500g or less and 52% were outborn. 
Neonatal specialist services include ‘pediatric cardiology’ and ‘cardiac surgery’.  
During the study period there was a progressive increase in nursing and medical staff  in accordance with 
the population increase. A protocol for catheter care was implemented in 2006 according to the 2002 
guidelines of the Centers for Disease Control and Prevention (CDC); before 2006 the norm ‘good 
practice’ was the standard. Furthermore, there were no changes in the antifungal and antimicrobial 
therapy protocols and no systematic antifungal prophylaxis was supplied.   
The NICAUDIT database was used to identify laboratory-confirmed HABSI cases. In addition, medical files 
of all incorporated HABSI cases were reviewed to determine the diagnostic certainty of infection. For 
HABSI cases, the following data were collected: ‘causative pathogen(s)’, ‘pre-infection days’, and 
‘preceding early-onset bloodstream infection’. For all included neonates the following demographical 
data and comorbidities were collected: ‘birth weight’, ‘gestational age’, ‘gender’, ‘length of stay’, 
‘mechanical ventilation’ and ‘length of mechanical ventilation’, ‘total parenteral nutrition’ (TPN) and 
‘length of TPN’, ‘surgery’ (abdominal, cardiac and other type), ‘gastrointestinal disease’, ‘renal 
insufficiency’, ‘intracranial hemorrhage’, ‘acute lung disease’, and ‘congenital malformations’. For very 
low birth weight neonates, CRIB score was calculated. 
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TABLE 1. Definite and Possible  Health Care-Associated Bloodstream Infection and Probable Contamination According to the Criteria of the 
National Institute of Child Health and Human Development 
 
Definitions  
A laboratory-confirmed HABSI is defined as one or more positive blood cultures obtained ≥72 hours of 
life. Exclusion was made for community-acquired HABSIs and infections due to vertical transmission, that 
is, transmission from mother to child. HABSIs were classified as  ‘probable contamination’,  ‘possible’ or 
‘definite’ according to the NICHD criteria (Table 1). Blood culture results considered as ‘probable 
contamination’ are not included in our cohort. For neonates with more than 1 HABSI, only the first 
episode was included. When the blood cultured pathogen was defined as ‘bacteria not specified’, the 
bacteria is considered as a nonrecognized pathogen and the criteria of the NICHD are used to classify the 
HABSI as ‘definite’ or ‘possible’. Polymicrobial HABSIs are defined as the presence of 2 or more 
pathogens in 1 blood culture. ‘Preinfection days’ are the days of admission before HABSI. ‘Length of stay’ 
are the number of days from admission to NICU to discharge for each patient.  
‘Gastrointestinal disease’ encompasses ‘necrotizing enterocolitis’ (all stages) and ‘intestinal perforation’. 
‘Renal insufficiency’ represents a transient, prolonged, or permanent creatininemia of > 1.5mg/dL ( = 
132.6 µmol/L). ‘Acute lung disease' includes ‘respiratory distress syndrome’ (type II), ‘pneumonia’, 
‘pulmonary hemorrhage’, ‘postasphyxia pulmonary oedema’, ‘aspiration pneumonitis’, and ‘pleural 
effusion’. ‘Intracranial hemorrhage’ clusters all interventricular hemorrhages except grade 1 (according 
HABSI Pathogen N of positive  
blood cultures 
Other criteria 
Definite  Recognized ie. Staphylococcus. aureus,   Enterococcus 
spp., Escherichia. coli, Pseudomonas spp., Klebsiella 
spp., Candida spp., and others. 
1 None 
 Possible/Skin contaminant ie.  Corynebacterium  spp., 
Bacillus (not B. anthracis) spp., Propionibacterium spp., 
CoNS spp., viridans group streptococci, Aerococcus 
spp., and Micrococcus spp. 
2  Blood drawn within 48h of each other 
(separate occasions) and having grown 








C-reactive protein > 1 mg/dl Anti-









Does not meet criteria ‘possible’ 
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to Volpe’s classification78), ‘(sub)epidural hemorrhage’, ‘lobar  intracranial hemorrhage’, ‘thalamo-
ventricular hemorrhage’, ‘subarachnoid hemorrhage’, and ‘cerebellar hemorrhage’. ‘Ductus ligature’, 
‘palliative shunt surgery’, and ‘corrective cardiac surgery’ are grouped as ‘cardiac surgery’. ‘Abdominal 
surgery’ included ‘bowel surgery’, ‘correction of diaphragmatic hernia’, ‘liver surgery’ or ‘biliary duct 
surgery’. ‘Other types of surgery’ were: ‘neurologic’, ‘ophthalmologic’, ‘orthopedic’, ‘plastic’, ‘ear-nose-
throat’, ‘urologic’, ‘multidisciplinary’.  
‘Mechanical ventilation’ is the number of days of mechanical ventilation during the entire period of 
hospitalization in NICU, from the admission to discharge. ‘TPN’ is the number of days of total parenteral 
nutrition (intravenous infusion by central or peripheral line of at least 2 major nutritional components, 
ie, carbohydrate and amino acids or lipids, without enteral nutrition), from the admission in NICU to 
discharge.  
Blood culture sampling and processing  
Blood cultures, that is, approximately 1mL per bottle, are obtained through an arterial central line or by 
peripheral puncture. There were no changes in blood culture sampling policy and no significant changes 
in total number of blood cultures taken yearly during the study period (mean 492, range 449-555). Blood 
cultures were assessed using the Bactec-system (Becton Dickinson Microbiology System, Sparks, NV) 
until 1995 and since 1996 BacT/Alert 3D automated microbial detection system (bioMérieux Inc., 
Durham, NC). 
Statistics 
Variables are described as mean (range), number (%) or median (interquartile range [IQR]).  Risk factors 
for HABSI were assessed by univariate analysis (Fischer exact or Mann-Whitney U test)  and when P value 
< 0.15 included in multivariate logistic regression analysis calculating adjusted odds ratios (aORs). For this 
analysis, a stepwise selection technique was used with ‘enter’ method; highest P values were rejected in 
a stepwise manner; two-tailed P values < 0.10 were retained for the final model. Since the variable 
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‘surgery’ is a cluster of three subgroups in order to discern the related incremental risk, the whole cluster 
was retained for the final model when one subgroups obtained a P values of < 0.10. Concerning ‘surgery’ 
as a multivariate risk factor, neonates undergoing more than one type of surgery were not included for 
multivariate regression analysis. The CRIB score value of 5 or more was chosen based on the results of 
linear regression analysis. Time-dependent variables are not included in multivariate analysis; 
‘mechanical ventilation’ and ‘TPN’ are included as dummy variables. The statistical package of social 
science version 21 was utilized for all tests (SPSS Inc, Chicago, IL). Hosmer and Lemeshow test, assessing 
goodness of fit for logistic regression models, was executed.   
RESULTS 
Incidence 
According to the NICAUDIT system,  5134 neonates survived the first 72 hours after birth and were 
admitted for 3 days or more of which 377 neonates developed a first-episode HABSI. After reviewing the 
377 medical files, 33 episodes were considered as ‘probable contamination’ and were excluded. Twelve 
neonates experienced an early-onset bloodstream infection (<72 hours after birth) preceding the first-
episode of HABSI. Two of them were excluded because the causative pathogen was identical to the 
early-onset episode. The final study cohort included 342 first-episode HABSIs. Of these, respectively 213 
(62.3%) and 129 (37.7%) were defined as ‘definite HABSI’ and ‘possible HABSI’. In total we observed a 
crude rate of 6.7% and an incidence density of 3.1 per 1000 hospital days. In the group of neonates with 
a birthweight ≤1500g we observed a crude incidence of 15.3% (149/973) of which 61% for ‘definite 
HABSI’. In the group of heavier neonates the crude rate of infection was 4.6% (193/3969), of which 63% 
for ‘definite HABSI’. Of all 342 HABSIs, 23 (6.7%) were polymicrobial of which 22 were defined as 
‘definite’. 
Neonatal characteristics  
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Of the 5134 included neonates, average birth weight and gestational age was respectively 2453 g (range, 
460-5300) and 35 weeks (range, 22-42). Of the average 513 yearly admissions of 3 days or more (range 
448-565), approximately 98 (range 83-113) were very low birth weight and approximately 108 (range 86-
129) were very low gestational age (≤31 weeks) neonates.  
For very low birth weight neonates, a significant decrease in mean CRIB score was observed comparing 
the first 5-year period (2002-2006, n = 2414) with the last 5-year period (2007-2011, n = 2720) (P < 
0.001); the median CRIB was respectively 0 (IQR 0-2) and 0 (IQR 0-1). As for very low birth weight HABSI 
cases, no trend and no significant difference was detected in mean CRIB score between the first and the 
last 5-year period. Furthermore, no significant difference in HABSI incidence, mean birth weight, and 
mean gestational age was noticed between the 2 periods.  
Pathogen distribution 
Pathogen distribution for the total cohort is tabulated in Table 2. More than half of the HABSIs were 
caused by coagulase-negative staphylococci (CoNS; 55.6%). Most common other gram-positive and 
gram-negative pathogens were respectively Staphylococcus aureus (15.6%) and Escherichia coli (5.2%). In 
17 of the 22 polymicrobial definite HABSIs, a recognized pathogen was mixed with a CoNS. The other 5 
blood cultures revealed mixed growth with another recognized pathogen. No significant difference in 
gram-positive and gram-negative pathogen distribution is observed between neonates weighing ≤1500g 
and >1500g. In contrast, significantly more neonates developed a HABSI caused by fungi in the ≤1500g 








Table 2. Pathogen Distribution of the 342 Health Care-Associated Bloodstream Infections 
Total gram-positive pathogens, n (%) 302 (82.7) 
    Coagulase-negative staphylococci, n (%) 203 (55.6) 
    Staphylococcus aureus, n (%) 57 (15.6) 
    Enterococcus spp., n (%) 20 (5.5) 
    Streptococcus agalactiae, n (%) 5 (1.4) 
    Streptococcus pneumonia, n (%) 3 (0.8) 
    Other gram-positive pathogens, n (%) 14 (3.8) 
Total gram-negative pathogens, n (%) 53 (14.5) 
    Escherichia coli, n (%) 19 (5.2) 
    Enterobacter spp., n (%) 14 (3.8) 
    Klebsiella spp., n (%) 9 (2.5) 
    Pseudomonas aeruginosa, n (%) 3 (0.8) 
        Other gram-negative pathogens, n (%) 8 (2.2) 
Candida spp., n (%) 7 (1.9) 
Bacteria not specified, n (%) 3 (0.8) 
Polymicrobial HABSIs, n (%) 23 (6.7) 
Total pathogens, n  365 
 
Univariate analysis 
Univariate risk factors for HABSI for the total, ≤1500g, and >1500g cohort are presented in Table 3. 
Concerning ‘NICU stay’, significantly greater length of stay was detected for HABSI cases in all cohorts. 
Concerning ‘time before infection’, the cohort > 1500g developed HABSI significantly earlier than the 
group on infants ≤1500g (P = 0.004). ‘TPN’, ‘intracranial hemorrhage’, and ‘acute lung disease’ were only 
associated with HABSI in the >1500g cohort; ‘other type of surgery’ was solely associated with HABSI in 
the ≤1500g cohort.  
Multivariate analysis 
Regression models for the total, ≤1500g, and >1500g cohort are displayed in Table 4. ‘Gastrointestinal 
disease’ and ‘cardiac surgery’ are independent risk factors for HABSI in infants ≤1500g as well as in those 
>1500g. ‘TPN’ is an additional independent risk factors for the >1500g cohort and ‘other type of surgery’ 
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and ‘mechanical ventilation’ are additional independent risk factors for the ≤1500g cohort. ‘Extremely 
low birth weight’ (≤1000g) is not an independent risk for HABSI in the ≤1500g cohort.  
DISCUSSION 
We described risk factors for HABSI in critically ill neonates stratified by birth weight and adjusting for 
initial severity of illness and several comorbidities. Independent risk factors for HABSI in the total cohort 
are: ‘TPN’, ‘very low birth weight’, ‘mechanical ventilation’, ‘gastrointestinal disease’, ‘surgery’ (cardiac 
and other type), and ‘renal insufficiency’. Risk stratification by birth weight revealed some difference 
although ‘gastrointestinal disease’ and ‘cardiac surgery’ remained independent risk factors in both birth 







Table 3. Univariate Risk Factors for the Total, ≤1500 g, and >1500 g Cohort 
Variable Total Cohort   ≤1500g Cohort >1500g Cohort  
HABSI Non HABSI P HABSI Non HABSI P HABSI Non HABSI P 
Patients, n 342 4792  149 823  193 3969  
Birth weight, g, median (IQR) 
     ≤ 1000g, n (%) 






2662 (1933-3320) 2769 (2110-3350) 0.062 
Gestational age, weeks, median (IQR) 



















Gender, male, n (%) 196 (57.3) 2802 (58.5) 0.828 82 (55.0) 411 (49.9) 0.512 114 (59.1) 2390 (60.3) 0.872 
CRIB score, median (IQR)     3 (1-7) 1 (1-4) <0.001    
Patients with CRIB score  ≥5, n (%)    54 (36.2) 188 (22.8) 0.009    
Patients with congenital malformation, n (%) 106 (31.0) 991 (20.7) <0.001 27 (18.1) 77 (9.3) 0.005 79 (40.9) 996 (25.1) <0.001 
Patients with mechanical ventilation, n (%) 223 (65.2) 1723 (36.0) <0.001 121 (81.2) 458 (55.6) 0.005 102 (52.8) 1265 (31.9) <0.001 
Patients with TPN, n (%) 332 (97.1) 3529 (73.6) <0.001 147 (99.3) 800 (97.1) 0.899 185 (95.9) 2729 (68.8) <0.001 
Patients with TPN  ≥14 days, n (%) 240 (72.3) 1014 (28.7) <0.001 134 (89.9) 478 (58.0) 0.001 106 (57.3) 536 (19.6) <0.001 
Patients with intracranial hemorrhage, n (%) 42 (12.3) 264 (5.5) <0.001 28 (18.8) 122 (14.8) 0.294 14 (7.3) 142 (3.6) 0.013 
Patients with acute lung disease, n (%) 49 (14.3) 538 (11.2) 0.125 13 (8.7) 68 (8.3) 0.860 36 (18.7) 470 (11.8) 0.015 
Patients with gastrointestinal disease, n (%) 



















Patients with renal insufficiency, n (%)  19 (5.6) 85 (1.8) <0.001 7 (4.7) 10 (1.2) 0.004 12 (6.2) 75 (1.9) <0.001 
Patients with surgery, n (%) 
     Cardiac, n (%)  
     Abdominal, n (%)  





































LOS, days, median (IQR) 41 (21-75) 13 (7-23) <0.001 69 (42-109) 37 (17-63) <0.001 36 (16-47) 15 (6-18) <0.001 
LOS before HABSI, days, median (IQR) 12.5 (7-21.5)   15 (8-23)   11 (6-19)   
Length of mechanical  



















Length of TPN, days, median (IQR) 20 (12-32) 6 (0-12) <0.001 28 (20-40) 15 (10-21) <0.001 21 (10-26) 9 (4-12) <0.001 
IQR, interquartile range; LOS, length of stay.          
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Table 4. Multivariate Regression Models for the Total, ≤1500 g, and >1500 g Cohort 
Total Cohort (n = 5134); 
0.187* 
Neonates with birth weight  ≤1500g, (n = 972); 
0.205* 
Neonates with birth weight >1500g (n = 4162); 
0.623* 
Risk factor aOR (95% CI)  P Risk factor aOR (95% CI) P Risk factor aOR (95% CI) P 
TPN 6.4 (3.2-12.8) <0.001    TPN  7.9 (3.9-16.2) <0.001 
Birth weight ≤1500g 2.8 (2.2-3.6) <0.001       
Mechanical ventilation 1.4 (1.0-1.8) 0.023 Mechanical ventilation 2.6 (1.6-4.0) <0.001    
Gastrointestinal disease 2.7 (2.0-3.6) <0.001 Gastrointestinal disease 2.0 (1.3-3.1) 0.003 Gastrointestinal disease 3.4 (2.4-4.9) <0.001 
Surgery  
(no surgery is reference category) 
     Abdominal surgery 
     Cardiac surgery 












(no surgery is reference category) 
     Abdominal surgery 
     Cardiac surgery 












(no surgery is reference category) 
     Abdominal surgery 
     Cardiac surgery 











Renal insufficiency 1.9 (1.1-3.3) 0.018 Renal insufficiency 2.5 (0.9-7.0) 0.074 Renal insufficiency  1.8 (0.9-3.5) 0.073 




An incidence of 6.7% (total cohort), 15.3% (neonates ≤1500g), and 4.6% (neonates >1500g) indicates that 
HABSI remains an important issue in our NICU in all birth weight groups. In comparison to the 
multicenter study of Stoll et al.10, reporting an incidence of 21% for very low birth weight neonates and 
using the same criteria for HABSI definition, our result of 15.3% is slightly lower. However, several 
episodes of HABSIs per neonate were included in their study possibly increasing their number The 
multicenter study of Testoni et al.79 reported an incidence of 3% for term neonates (median gestational 
age 39, IQR 37-41) although we note that other criteria were used for defining ‘health care-associated’ 
(occurrence between days 4 and 120 days of life) and for a bloodstream infection caused by a 
nonrecognized pathogen. In addition, they excluded neonates with major congenital anomalies and 
neonates who had surgery before day of life 120. In contrast, our cohort of neonates >1500g were 
younger gestational age (median 36, IQR 33-39) and did include neonates with congenital anomalies and 
undergoing surgery. For this reason, our cohort can be perceived as more critically ill resulting in a higher 
HABSI incidence rate. The study of Crivaro et al.76 demonstrated substantial incidence densities for 
neonates >1500g ranging from 0.9 to 7.0 per 1000 specific device days, although incidence were not 
reported.  
Risk factor analyses 
For the total cohort, it is observed that all variables, except for ‘male gender’ and ‘acute lung disease’, 
are associated with HABSI. Differences in associated variables are observed for the birth weight cohorts, 
that is, for ‘TPN’, ‘intracranial hemorrhage’, ‘acute lung disease’ and ‘other type of surgery’. Remarkable 
are the significantly fewer days before HABSI (minus 4 days) for the >1500g compared to the ≤1500g 
cohort (P = 0.004). Since time to infection can be placed in the context of exposure time and type of 
catheter, this association may reasonably be expected in the very low birth weight cohort.59 The shorter 
time to infection in the >1500g cohort might indicate the need for improved catheter care in this cohort. 
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Concerning ‘CRIB score’, a decrease is noticed during the study period for the very low birth weight 
cohort, probably reflecting better prenatal and postnatal care in the first hours of life.80 Nevertheless, 
higher CRIB scores and a higher proportion CRIB ≥ 5 were observed throughout the study period for very 
low birth weight HABSI cases versus nonHABSI cases probably meaning that initial severity of disease 
soon after birth appears to be an indicator for HABSI as also suggested by Fowlie et al.81 Though an 
association between ‘CRIB’ and ‘HABSI’ was found, ‘CRIB ≥ 5’ was no independent risk factor for HABSI in 
the ≤1500g cohort. This result agrees with the findings of Auriti et al.73 although their results were based 
on prediction of ‘health care-associated infections’ and not solely ‘bloodstream infections’. But this 
results is in contrast with another study of Auriti et al.22 that used ‘CRIB ≥4’ for health care-associated 
infection prediction which might explain the difference in result. ‘TPN’ is generally accepted as an 
important risk factor in particular for CoNS HABSIs82-85. However, in our very low birth weight cohort, 
‘TPN’ was not associated with HABSI. This is because of a lack of discriminatory power as nearly all very 
low birth weight neonates (both HABSI and nonHABSI cases) received TPN. In the study of Auriti et al.22 
‘parenteral nutrition’, defined as lipid-containing parenteral nutrition, was also not included in 
multivariate regression analysis for neonates ≤1500g, meaning that there was no association with sepsis 
as well. As in other studies, ‘mechanical ventilation’ is an independent risk factor for HABSI in the ≤1500 
g cohort.8, 10, 35 For the >1500 g cohort, ‘mechanical ventilation’ was, once adjusted for other variables, 
no risk factor. It is well known that optimal gastrointestinal flora is a protective factor for infections.16, 51, 
86 In our study, incidence of HABSI is highest in neonates with a gastrointestinal disease (18.3%). In 
addition, ‘gastrointestinal disease’ is an independent risk factor for HABSI both for very low birth weight 
infants and newborns greater than 1500g. This finding is in contrast to the results of Padula et al.87 The 
latter included solely neonates of whom blood cultures were drawn for suspicion of HABSI (n=409) so 
the variance in research population might explain the difference in result. As in the study of Boghossian 
et al.88, ‘surgery’ is an independent risk factor in the very low birth weight cohort. In our study, ‘surgery’ 
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is also an independent risk factor in the >1500g cohort. Since cardiac surgery is a specialist service in our 
center a large cohort consisting of 92% neonates weighing > 1500g (379/413)  could be evaluated. Our 
results suggest an incremental risk for ‘cardiac’ compared to ‘abdominal surgery’ which is even no 
significant independent risk factor. Possibly, the relative risk of abdominal surgery is of no or minor 
importance once adjusted for the underlying gastrointestinal disease process. To our knowledge, no 
other study searched for the potential association of renal insufficiency and HABSI. Impaired renal 
function appears to be an independent risk factor for the total cohort, although for the separate birth 
weight cohorts the risk was no longer significant. The very low birth weight cohort included only 17 
neonates with renal insufficiency, so lack of power might have influenced our results. Renal insufficiency 
might reflect the initial severity of illness in neonates which can explain the risk for sepsis. In addition, 
oliguria is a recognized symptom associated with HABSI.56 However, the risk might be inverted because it 
is well known that severe sepsis can result in renal impairment.89 Further prospective research on 
creatininemia as a determinant for HABSI might clarify this issue.  
Limitations and recommendations 
Our study has limitations inherent to the historical single-center design. However, the single-center 
design may act as a strength because this has led to a homogenous standard of care applicable to both 
patients with and without HABSI. Certainty of HABSI diagnosis was controlled by additional review of 
medical files and by solely including ‘definite’ and ‘possible’ HABSIs. However, we cannot rule out that 
some patients with HABSI were not identified as such. We note that mechanical ventilation can be 
instituted after an episode of HABSI and that surgery and renal failure may be a consequence of HABSI. 
Nonetheless, risk for HABSI encompasses the total hospitalization period on the NICU. In addition, the 
necessity of mechanical ventilation for very low birth weight neonates and cardiac surgery in all 
neonates is most probably short after birth.  
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The need for necrotizing enterocolitis prevention initiatives is emphasized since ‘gastrointestinal disease’ 
is an independent risk factor for HABSI in all birth weight groups; optimizing gastrointestinal flora by, for 
example, limiting the duration of parenteral nutrition, appropriate preparation and administration of 
parenteral nutrition, appropriate and shorter duration of antibiotic therapy, and breastfeeding can be 
recommended.52, 74, 90 Further research is needed for other controversial  prevention initiatives such as 
probiotics administration (preparation and length of administration) and early promotion and slow 
advancement of enteral feeding.90-95 Also, more large randomized controlled trials are needed for 
exploring the true effect of probiotic administration on HABSI as conducted by Jacobs et al.96; a 
nonsignificant reduction of HABSI (although an absolute reduction of 3.1% which is clinically relevant) 
was observed in their double-blinded randomized controlled trial. Furthermore, it might be interesting to 
explore the ‘gastrointestinal disease’ cohort in a prospective research; as such, the impact of the several 
necrotizing enterocolitis stages, (spontaneous) intestinal perforation, and congenital malformations, 
such as gastroschisis on HABSI can be clarified. Also, it might be interesting to further investigate the 
impact of a gastrointestinal disease on mortality in neonates with and without HABSI and additionally 
the impact of HABSI on mortality stratified by birth weight and adjusted for initial severity of illness and 
underlying comorbidities. Finally, we note that therapeutic management of HABSI cannot solely depend 
on risk factors. Risk factor based management in asymptomatic neonates might lead to overtreatment 
and antibiotic resistance, so considering the individual clinical context is warranted.52, 97-99 
CONCLUSION 
In our NICU, ‘TPN’, ‘mechanical ventilation’, ‘gastrointestinal disease’, ‘very low birth weight’, ‘surgery’ 
(cardiac and other type), and ‘renal insufficiency’ are independent risk factors for HABSI in the total 
cohort. Adjusting for several comorbidities, ‘cardiac surgery’ and ‘gastrointestinal disease’ remain risk 
factors in both birth weight cohorts so these patient groups need our special attention concerning 
infection control practices. For neonates >1500g, additional focus on adherence to catheter care 
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standards or revising current standards is recommended; for neonates ≤1500g, care for ventilated 
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Objective: Healthcare-associated sepsis (HAS) is a life-threatening complication in neonatal intensive 
care. Research on impact of HAS on mortality adjusted for comorbidities is limited. We aim to describe 
impact of HAS on mortality stratified by birth weight and risk factors for mortality in neonates with HAS.  
Methods: We performed a historical cohort study. Logistic regression was used to calculate adjusted 
odds for mortality. HAS was defined according to the National-Institute-of-Child-Health-and-Human-
Development-criteria. Three-hundred-forty-two infants developed HAS in 5,134 admissions (6.7%). 
Results: Mortality in the total and HAS cohort was respectively 5.6% and 10.5%. The majority of HAS was 
caused by commensals (HAS-COM, 59.4%); 40.6% was caused by recognized pathogens (HAS-REC). 
Adjusted for comorbidities, ‘HAS-REC’ is only a risk factor for mortality in newborns weighing >1,500 
gram (adjusted odds ratio [aOR] 2.3, confidence interval [CI] 1.1-4.9). Post hoc analysis revealed that 
‘HAS-REC’ is an independent risk factor for mortality in infants with a gastrointestinal disease (aOR 4.8, CI 
2.1-10.8). ‘Renal insufficiency’ and ‘gastrointestinal disease’ are independent risk factor for mortality in 
the HAS cohort (respectively aOR 11.8, CI 4.4-31.0; aOR 2.3, CI 1.1-4.9).  
Conclusion: For very low birth weight infants (≤1,500 gram), several comorbidities overrule the impact of 
HAS on mortality. Special attention is for HAS-REC, in particular in heavier infants and infants with a 











Healthcare-associated sepsis (HAS) is a frequent complication in neonatal intensive care units (NICUs). 
Previous studies document incidence rates up to 32% 8, 10, 25, 71. HAS is particularly more prevalent in 
neonates with very low birth weight (≤ 1,500 gram), gastrointestinal disease, higher severity of illness at 
birth, and undergoing a major surgical procedure 10, 22, 73, 100. Although implementation of new knowledge 
by means of care bundles and infection control practices might decrease the incidence, HAS remains a 
leading cause of morbidity and can be life-threatening. HAS can result in prolonged hospitalization (on 
average, plus 3 weeks),  neurodevelopmental deficiency, growth impairment, and a rise in mortality rate 
up to 24% for very low birth weight neonates 15, 18, 27-29, 37. Underlying conditions such as low gestational 
age, need for intubation, congenital malformation, cardiac pathology, etc. may compromise survival 2, 101. 
Consequently, as the relationship between HAS and mortality can be confounded by comorbidities, the 
true effect on mortality of this infectious complication is difficult to assess. In addition, the risk of death 
might differ according to the causative pathogen and its antimicrobial susceptibility pattern; in particular 
gram-negative pathogens and fungi are associated with higher mortality rates 9, 10, 65, 102, 103. Furthermore, 
studies on risk factors for in-hospital mortality in infants with HAS are limited. The objective of this study 
was to assess the impact of HAS on mortality in critically ill infants stratified by birth weight, ie. ≤ 1500 
gram or > 1500 gram. In addition, risk factors for mortality in infants with HAS were identified.  
MATERIALS AND METHODS 
Setting and patient population 
All newborns admitted for at least 3 days with a maximum of 150 days during a 10-year period (2002-
2011) in Ghent University Hospital (a Belgian tertiary referral center with 32 NICU beds), were eligible for 
inclusion. Approximately 533 neonates per year were admitted over the past 10 years of which 98 were 
very low birth weight neonates. Ghent University Hospital’s neonatal specialist services are: pediatric 
cardiology (on average 70 neonatal case/year) and cardiac surgery (on average 50 neonatal cases/year). 
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The study was approved by the Ethics Committee of Ghent University Hospital. 
Study design and data collection 
We performed a single-center historical cohort study. A NICAUDIT database was used for patient 
identification and to identify laboratory-confirmed HAS cases. In addition, medical files of all 
incorporated HAS cases were reviewed by the principal investigator to determine the diagnostic 
certainty of the infection. Through the NICAUDIT database following demographic data and 
comorbidities were collected: ‘birth weight’, ‘gestational age’,’ gender’, ‘length of stay’, ‘mechanical 
ventilation’ and ‘length of mechanical ventilation’, ‘surgery’, ‘gastrointestinal disease’, ‘renal 
insufficiency’, ‘intracranial hemorrhage’, ‘acute lung disease’, ‘chronic lung disease’, ‘leukomalacia’, 
‘asphyxia’, ‘congenital malformations’, and ‘late-onset in-hospital mortality’ (> 72 hours). For very low 
birth weight neonates the Clinical Risk Index for Babies (CRIB) score was calculated. The CRIB score, 
validated in neonates ≤ 31 weeks of gestational age, evaluates the severity of illness during the first 12 
hours of life and the risk for mortality by calculating the sum of six parameters (ie. ‘birth weight’, 
‘gestational age’, ‘minimum FiO2’, ‘maximum FiO2’, ‘congenital malformation’, and ‘maximum base 
excess’)77. For HAS cases, following data were collected: the number of separate episodes (ie. the same 
organism was cultured after 10 days of appropriate antibiotic therapy or if a different organism was 
cultured from a subsequent culture), the causative pathogen(s), the antimicrobial resistance pattern.  
Blood culture sampling process 
Blood cultures with approximately 1mL per bottle were sampled through an new central line or by 
peripheral puncture. There were no changes during the study period in blood culture sampling process, 
ie. in frequencies, technique, and assessing system (BacT/Alert 3D automated microbial detection 




Laboratory-confirmed sepsis is considered healthcare-associated when one or more positive blood 
cultures are obtained after 72 hours of life and is defined according to the National Institute of Child 
Health and Human Development criteria.10 HAS deliberated as ‘probable contamination’ are not included 
in our cohort. Recognized pathogens for HAS in neonates are: Staphylococcus aureus, Enterococcus spp., 
Group B Streptococcus spp., Pneumococcus spp., Pseudomonas spp., enterobacteriaceae (mainly 
Enterobacter spp., Klebsiella spp., and Escherichia coli), and fungi (mainly Candida spp.); HAS caused by 
recognized pathogens are further termed as HAS-REC. Included nonrecognized pathogens for neonatal 
HAS are generally skin commensals, ie. coagulase-negative Staphylococcus (CoNS) spp. and viridans 
streptococcal spp.10 When the causative pathogen was a skin commensal (HAS-COM), extra criteria were 
required for the diagnosis of HAS, ie. a second blood culture within 48 hours of each other and having 
grown the same pathogen or one positive blood culture and a C-reactive protein > 1 mg/dL plus 
antimicrobial therapy for ≥ 5 days. 10  
Polymicrobial HAS is defined as the presence of two or more pathogens in one blood culture. 
Antimicrobial resistance patterns are described for Staphylococcus spp., ie. methicillin resistance, 
Enterococcus spp., ie. vancomycin resistance, and gram-negative pathogens, ie. cephalosporin resistance 
for enterobacteriaceae and multiple resistance (≥2) for Pseudomonas spp..  
‘Gastrointestinal disease’ encompasses ‘necrotizing enterocolitis’ (suspected, definite, and advanced 
without perforation) and ‘intestinal perforation’ (focal and advanced necrotizing enterocolitis with 
perforation). ‘Renal insufficiency’ represents a transient, prolonged, or permanent serum creatinine of > 
1.5 mg/dL ( = 132.6 µmol/L). ‘Acute lung disease' includes ‘respiratory distress syndrome’ (type II), 
‘pneumonia’, ‘pulmonary hemorrhage’, ‘post-asphyxia pulmonary oedema’, ‘aspiration pneumonitis’, 




Variables are described as number (%) or median (interquartile range [IQR]).  Risk factors for mortality 
for the total, HAS, and birth weight cohorts (≤ 1500 gram or > 1500 gram) were assessed by univariate 
analysis (Fischer exact or Mann-Whitney U test) and when p value < 0.15 included in multivariate logistic 
regression calculating adjusted odds ratio’s (aOR) with 95% confidence intervals (CI). For these analyses, 
only the last-episode HAS was included and a stepwise selection technique was used with ‘enter’ 
method; highest p values were stepwise rejected; two-tailed p values < 0.10 were retained for the final 
model. ‘HAS’ was retained in regression modelling even when the p value exceeded 0.10 considering our 
research question. Because of collinearity between ‘gestational age’ and ‘birth weight’ and between 
‘mechanical ventilation’ (> one week) and ‘mortality’, ‘gestational age’ and ‘mechanical ventilation’ were 
excluded for regression modeling; a predictor/event ratio of approximately 1/10 will be applied in order 
to avoid overfitting. Survival analysis for neonates with and without HAS was executed by a Kaplan Meier 
curve with Logrank test. The statistical package of social science (SPSS) version 21 was used for all tests 
(SPSS Inc, Chicago, IL).  
RESULTS 
Incidence, univariate risk factors, and survival 
According to the NICAUDIT system,  5,134 neonates were admitted between three and 150 days; their 
median birth weight and gestational age was respectively 2,430 gram (1,715-3,220) and 35 weeks (32-
39). Of the 5,134 included neonates, 377 neonates developed a HAS. After reviewing the 377 medical 
files, 35 episodes were considered as ‘probable contamination’ and were excluded. The final HAS cohort 
included 342 neonates of which 20 developed a second and five a third episode. This is a total incidence 
of 7.1% and an incidence density of 3.3 per 1,000 hospital days. The rate of infants receiving total 
parenteral nutrition was 75.2% (3861/5134) and incidence per 1000 total parenteral nutrition days was 
7.9 (7.4-9.1). Characteristics and univariate risk factors for the total and HAS cohort are displayed in 
Table 1; for the birth weight cohorts in Table 2. A HAS episode is  associated with mortality in the total 
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and > 1500 gram birth weight cohort. When dividing HAS according to causative pathogen, HAS-REC is 
associated and HAS-COM is not associated with mortality in any of the cohort studied. 
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TABLE 1. Characteristics and Univariate Risk Factors for In-Hospital Mortality for the Total and Infection Cohort 
Risk factor Total Cohort  (n = 5,134) 
      Dead                              Survived                           p  
     (n = 288)                        (n = 4,846) 
HAS Cohort (n = 342) 
    Dead                                Survived                             p 
    (n = 36)                              (n = 306)   
Birth weight, gram  2,043 (976-2,983) 2450 (1,750-3,230) <0.001 1,388 (744-2,231) 1,795 (1,123-2,880) 0.022 
     1,001 – 1,500 gram, n (%)  38 (13.3) 608 (12.5) 0.747 8 (22.2) 73 (23.9) 0.827 
     751 – 1,000 gram, n (%) 35 (12.2) 187 (3.9) <0.001 3 (8.3) 37 (12.1) 0.507 
      ≤ 750 gram, n (%) 41 (14.2) 64 (1.3) <0.001 9 (25.0) 20 (6.5) <0.001 
Gestational age, weeks 34 (28-38) 36 (32-39) <0.001 31 (27-35) 33 (29-38) 0.044 
   ≤31 weeks, n (%) 110 (38.2) 972 (20.1) <0.001 18 (50.0) 131 (42.8) 0.478 
Gender, male, n (%) 196 (68.1) 2802 (57.8) 0.673 19 (52.8) 180 (58.8) 0.482 
Acute lung disease, n (%) 70 (24.3) 517 (10.7) <0.001 8 (22.2) 43 (14.1) 0.215 
Asphyxia, n (%) 42 (14.6) 35 (0.7) <0.001 1 (2.8) 4 (1.3) 0.429 
Cerebral hemorrhage, n (%) 89 (30.9) 217 (4.5) <0.001 9 (25.0) 33 (10.8) 0.027 
Chronic lung disease, n (%) 29 (10.1) 312 (6.4) 0.020 13 (36.1) 74 (24.2) 0.155 
Congenital malformations, n (%) 114 (39.6) 983 (20.3) <0.001 16 (44.4) 91 (29.7) 0.087 
Gastrointestinal disease, n (%) 40 (13.9) 458 (9.5) 0.018 15 (41.7) 75 (24.5) 0.043 
HAS, n (%) 
      by recognized pathogen 










   
Leukomalacia, n (%) 51 (17.7) 232 (4.8) <0.001 11 (30.6) 42 (13.7) 0.014 
Mechanical ventilation, n (%) 269 (93.4) 1677 (34.6) <0.001 36 (100.0) 191 (62.4) <0.001 
Renal insufficiency, n (%) 41 (14.2) 63 (1.3) <0.001 10 (27.8) 10 (3.3) <0.001 
Surgery, n (%) 66 (22.9) 765 (15.8) 0.001 17 (47.2) 113 (36.9) 0.276 
Length of stay, days  6 (3-17) 14 (8-26) <0.001 35 (10-76) 44 (22-76) 0.050 
Mechanical ventilation, days 5 (3-10) 4 (2-8) <0.001 14 (6-38) 9 (4-14) 0.016 
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TABLE 2. Characteristics and Univariate Risk Factors for In-Hospital Mortality for the Birth weight Cohorts 
Risk factor ≤1,500 gram Cohort  (n = 973) 
      Dead                                Survived                             p  
    (n = 114)                           (n = 859) 
>1,500 gram Cohort (n = 4,161) 
Dead                          Survived                          p 
      (n = 174)                     (n = 3,987) 
Birth weight, gram  863 (708-1,150) 1,200 (965-1,365) <0.001 2,820 (2,196-3,310) 2,745 (2,100-3,350) 0.754 
Gestational age, weeks 27 (25-29) 29 (28-31) <0.001 38 (35-39) 37 (34-39) 0.009 
Gender, male, n (%) 64 (56.1) 429 (49.9) 0.232 105 (60.3) 2400 (60.2) 1.000 
CRIB 7 (4-10) 1 (1-4) <0.001    
     CRIB ≥5, n (%) 83 (72.8) 159 (18.5) <0.001    
Acute lung disease, n (%) 25 (21.9) 56 (6.5) <0.001 45 (25.9) 461 (11.6) <0.001 
Asphyxia, n (%) 1 (0.9) 2 (0.2) 0.312 41 (23.6) 33 (0.8) <0.001 
Cerebral hemorrhage, n (%) 67 (58.8) 83 (9.7) <0.001 22 (12.6) 134 (3.4) <0.001 
Chronic lung disease, n (%) 23 (20.2) 269 (31.3) 0.016 6 (3.4) 43 (1.1) 0.015 
Congenital malformations, n (%) 25 (21.9) 76 (8.8) <0.001 89 (51.1) 907 (22.7) <0.001 
Gastrointestinal disease, n (%) 21 (18.4) 148 (17.2) 0.792 19 (10.9) 310 (7.8) 0.149 
HAS, n (%) 
       by recognized pathogen 
       by skin commensal  
20 (17.5) 

















Leukomalacia, n (%) 29 (25.4) 162 (18.9) 0.103 22 (12.6) 70 (1.8) <0.001 
Mechanical ventilation, n (%) 113 (99.1) 466 (54.2) <0.001 156 (89.7) 1211 (30.4) <0.001 
Renal insufficiency, n (%) 11 (9.6) 6 (0.7) <0.001 30 (17.2) 57 (1.4) <0.001 
Surgery, n (%) 19 (16.7) 98 (11.4) 0.124 47 (27.0) 667 (16.7) <0.001 
Length of stay, days  7 (4-22) 46 (24-75) <0.001 6 (3-11) 12 (7-19) <0.001 
Time to HAS, days  12 (7-20) 14 (9-21) 0.205 14 (5-35) 9 (5-15) 0.255 
Mechanical ventilation, days 5 (3-14) 6 (2-12) 0.490 5 (3-9) 4 (2-6) <0.001 






TABLE 3. Pathogen Distribution for the Total Cohort 
Pathogens Total (n = 365) 
Total gram-positive pathogens, n (%) 302 (82.7) 
    Coagulase-negative staphylococci 203 (55.6)  
    Staphylococcus aureus 57 (15.6) 
    Enterococcus spp. 20 (5.5) 
    Group B Streptococcus spp. 5 (1.4) 
    Pneumococcus spp. 3 (0.8) 
    Other gram-positive pathogens 14 (3.8) 
Total gram-negative pathogens, n (%) 53 (14.5) 
    Escherichia coli 19 (5.2) 
    Enterobacter spp. 14 (3.8) 
    Klebsiella spp. 9 (2.5) 
    Pseudomonas spp. 3 (0.8) 
   Other gram-negative pathogens 8 (2.2) 
Candida spp., n (%) 7 (1.9) 
Bacteria not specified, n (%) 3 (0.8) 
Polymicrobial, n (%) 23 (6.7) 
   
 
 
Figure 1. Kaplan Meier curve for 150-days survival of neonates with and without sepsis   
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Significant shorter time to death, ie. length of stay for infants who died, is observed for neonates with 
birth weight > 1,500 gram compared to the very low birth weight neonates (respectively median 6 days, 
IQR 3-11 vs. median 7 days, IQR 4-22, p = 0.035). 
For the total cohort, logistic regression analysis revealed a 4-fold increased odds (unadjusted OR 4.0, CI 
2.6-6.1, p < 0.001) for mortality for neonates with HAS-REC versus HAS-COM. Survival of neonates 
without HAS and with HAS stratified by causative pathogen (ie. caused by skin commensal or recognized 
pathogen) is represented in Figure 1 by a Kaplan Meier curve. The 150-days survival was significantly 
lower for infants with HAS-REC (p = 0.001; Log-Rank test).   
Pathogens and mortality  
The 342 first-episode HAS were caused by 365 pathogens; 23 (6.7%) were polymicrobial HAS. Detailed 
pathogen distribution of the 342 first-episode HAS is tabulated in Table 3.  
No significant difference in gram-positive and gram-negative pathogen distribution was observed 
between very low birth weight and heavier neonates: respectively 81.3% gram-positive pathogens vs. 
80.1% (p = 0.888), 14.7% gram-negative pathogens vs. 18.8% (p = 0.318). In contrast, significantly more 
very low birth weight neonates developed a HAS caused by fungi (3.3% vs. 0.5% for >1500 g neonates, p 
= 0.049).  
Overall mortality was 5.6% (288/5134). Mortality for the HAS cohort was 10.5% (36/342) and for the 
birth weight subgroups 11.7% (114/973; ≤ 1,500 gram) and 4.2% (174/4161; > 1,500 gram) respectively. 
Table 4 displays antimicrobial resistance and mortality of the 342 last-episode pathogens. Three out of 7 
(43%) infants with a HAS caused by a cephalosporin resistant enterobacteriaceae died.  
Unadjusted regression analysis of the HAS cohort revealed no increased odds for mortality when a HAS is 
caused by an antibiotic resistant pathogen. In contrast, a second or more HAS episode revealed a tripled 
increased odds for mortality (unadjusted OR 3.0, CI 1.2-7.5, p = 0.001).  
Impact of HAS on mortality 
62 
 
Independent risk factors for in-hospital mortality for the total cohort are displayed in Table 5; for the 
birth weight cohorts in Table 6. When including ‘HAS’ (all pathogens, ie. HAS-COM and HAS-REC), in 
multivariate regression analysis as well as for the total, ≤ 1500 gram, and > 1500 gram cohort, ‘HAS’ was 
not independently associated with mortality (data not shown). Concerning the total cohort, ‘HAS-REC’ is 
no significant independent risk factor for mortality. Contrariwise, for the cohort of neonates weighing > 
1,500 gram, ‘HAS-REC’ is a significant independent risk factor for mortality. In this cohort of heaver 
neonates, HAS-REC represents 85 out the 192 HAS (44.2%) of which 36 (42%) were caused by gram-
negative pathogens.  
Post hoc analysis was executed for neonates with a gastrointestinal disease (n = 498). In the 
gastrointestinal disease cohort, HAS-REC represents 39 out 90 HAS (43.3%) of which 21 (53.8%) were 
caused by a gram-negative pathogen; HAS-REC has an almost 5-fold increased odds for mortality (aOR 
4.8, CI 2.1-10.8, p < 0.001), after adjustment for ‘very low birth weight’ (aOR 3.4, CI 1.6-7.3, p = 0.001) 
and ‘congenital malformations’ (aOR 3.7, CI 1.8-7.7, p = 0.001).   
Concerning the HAS cohort, ‘renal insufficiency’ (aOR 11.8, CI 4.4-31.0, p < 0.001) and ‘gastrointestinal 














NA, not applicable. 
 
TABLE 5. Independent Risk Factors for In-Hospital Mortality for the Total Cohort 
Risk factor aOR (95% CI)  P 
Asphyxia 56.8 (32.6-94.1) <0.001 
Cerebral hemorrhage  8.3 (5.8-11.7) <0.001 
Renal insufficiency 7.1 (4.1-11.9) <0.001 
Congenital malformation 5.9 (4.2-8.4) <0.001 
Birth weight  
(>1,500 gram is reference category) 
     1,001 – 1,500 gram 
     751 – 1,000 gram 












HAS, no is reference category 
     by recognized pathogen 









aOR, adjusted odds ratio; CI, confidence interval; HAS, healthcare-associated sepsis  
 
TABLE 6. Independent Risk Factors for In-Hospital Mortality for the Birth weight Cohorts 
                                                                            ≤1,500 gram Cohort (n=973)                     >1,500 gram Cohort (n = 4,161)  
Risk factor aOR (95% CI) P aOR (95% CI) P 
Acute lung disease   2.2 (1.5-3.4) <0.001 
Asphyxia   50.1 (27.4-87.2) <0.001 
Cerebral hemorrhage  13.7 (7.9-23.7) <0.001 2.5 (1.4-4.8) 0.003 
Congenital malformation 5.2 (2.6-10.3) <0.001 6.6 (4.4-10.1) <0.001 
CRIB ≥5 8.8 (5.2-14.9) <0.001   
HAS, no is reference category 
     by recognized pathogen 













Leukomalacia    2.7 (1.4-5.4) 0.004 
Renal insufficiency 15.8 (3.7-68.6) <0.001 6.3 (3.5-11.4) <0.001 
Surgery   0.6 (0.4-0.9) 0.024 
aOR, adjusted odds ratio; CI, confidence interval; CRIB, clinical risk index for babies; HAS, healthcare-associated sepsis 
 




(n = 342) 
Resistant to 
antibiotics 
(n = 172) 
Mortality 
 
(n = 36) 
Mortality +  
resistant to 
antibiotics (n = 9) 
Total gram-positive pathogens, n (%) 277 (81.0)  163 (94.8) 16 (44.4) 6 (66.7) 
     Coagulase-negative staphylococci 175 (51.2) 154 (89.5) 8 (22.2) 6 (66.7) 
     Staphylococcus aureus 56 (16.4)  7 (4.1) 5 (13.9) 0  
     Enterococcus spp. 21 (6.1) 2 (1.2) 2 (5.6) 0 
     Streptococcus agalactiae 5 (1.5)  NA 0 NA 
     Streptococcus pneumonia 3 (0.9)  NA 0 NA 
     Viridans group Streptococcus spp.  17 (5.0)  NA 1 (2.8) NA 
Total gram-negative pathogens, n (%) 58 (17.0)  9 (5.2) 16 (44.4) 3 (33.3) 
     Escherichia coli 21 (6.1)  1 (0.6) 2 (5.6) 1 (11.1) 
     Enterobacter spp. 17 (5.0)  4 (2.3) 6 (16.7) 1 (11.1) 
     Klebsiella spp. 10 (2.9)  2 (1.2) 3 (8.3) 1 (11.1) 
     Pseudomonas aeruginosa 3 (0.9)  1 (0.6) 1 (2.8) 0 
     Other or not specified gram-negative pathogen 7 (2.0)  NA 4 (11.1) NA 
Candida spp., n (%) 6 (1.8)  NA 3 (8.3) NA 




We described risk factors for in-hospital mortality with special emphasis on impact of HAS. For both birth 
weight cohorts, ‘HAS-REC’ is associated and ‘HAS-COM’ is not associated with in-hospital mortality. 
Adjusted for several comorbidities, ‘HAS-REC’ is observed to be a risk factor for mortality in neonates 
with birth weight > 1500 gram. Also for infants with a gastrointestinal disease, ‘HAS-REC’ seems to be an 
independent risk factor for mortality. ‘Renal insufficiency’ and ‘gastrointestinal disease’ appear to be 
independent risk factors for mortality in the HAS cohort.  
Incidence of mortality and pathogen distribution 
As in other studies, mortality was highest in neonates with very low birth weight 2, 101.  Mortality in our 
HAS group (10.5%) and very low birth weight HAS group (11.7%) was lower compared to other studies 
(respectively 13% to 17% and 15% to 26%) 8, 10, 65. This lower mortality rate is probably due to less gram-
negative HAS in our cohort as well as less HAS caused by fungi. Interestingly is the significant shorter 
time to death for infants with birth weight >1,500 gram; a higher proportion congenital malformations 
and in particular life-threatening malformations, might be responsible for earlier death.  
Risk factor analysis 
For the very low birth weight cohort, ‘HAS’ is, in univariate analysis, not associated with mortality which 
is in contrast with 2 other studies 10, 104. Those 2 studies were large multicenter researches including a 
diverse sample of NICUs which might be responsible for the difference in result. In addition, compared to 
Hornik et al.104 our cohort consist of 20% more gram-positive HAS and 27% more CoNS HAS. For this, the 
significant association of ‘HAS-REC’ is probably a more accurate comparison. Nevertheless, our findings 
are in line with the results of a recent multicenter study by Rozanska et al.105 including very low birth 
weight neonates with early- and late-onset bloodstream infection, pneumonia, and necrotizing 
enterocolitis. Also, no significant association was found for infection and in-hospital mortality. 
Unfortunately, no data on pathogen distribution was reported, no multivariate regression analysis was 
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executed, and no distinction was made between early- and late-onset infection so the adjusted impact of 
HAS on in-hospital mortality is not known. 
For heavier neonates, in contrast to Testoni et al.79, we could not confirm that  ‘HAS’ (all pathogens) is an 
independent predictor for mortality. The study cohort of Testoni et al.79 included solely neonates ≥ 37 
weeks gestational age (median 39 [37-41]) of the same diverse sample of NICUs as Hornik et al.104. The 
median gestational age of our >1,500 gram single-center cohort was 37 weeks (34-39) so case mix might 
be the reason for difference in result. Also, as stated earlier, our cohort consist of 20% more gram-
positive HAS and 27% more CoNS HAS compared to Hornik et al.104 which also can be responsible for the 
difference in result for ‘HAS’ and the affirmative result for ‘HAS-REC’. Nonetheless, different confounders 
were used in multivariate logistic regression analysis, so the results are incomparable. Our result that 
HAS-REC is an independent risk factor for infants with a birth weight more than 1500g and not for infants 
with a VLBW is unexpected, and will need external validation. It is an interesting observation that 
potentially other comorbidities overrule the impact of HAS-REC on mortality in VLBW infants. This 
observation is difficult to interpret because of several potential underlying mechanisms contributing to 
death. Also, the causal relationship between comorbidities and HAS cannot be determined in this study 
since initiation date of the included (co)morbidities were not registered. To explore this causal 
relationship, a prospective study can be recommended. 
Post hoc analysis with a high-risk subgroup, ie. infants with a gastrointestinal disease, revealed that ‘HAS-
REC’ is a risk factor for mortality once adjusted for other comorbidities. The strong association between 
‘gastrointestinal disease’ and ‘HAS’ in previous research prompted our special interest 100. The relation 
between disturbed intestinal microbial flora and sepsis is well known, in particular in low birth weight 
neonates 16, 51, 86. A decreased intestinal barrier function can make the gut prone to gram-negative 
colonization which may translocate to the bloodstream 51. In this study, the gastrointestinal disease 
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cohort had the highest rate of gram-negative HAS. Probably due to this high rate, ‘HAS-REC’ appears to 
be an independent risk factor for mortality. 
Regarding unadjusted risk for mortality in the HAS cohort, ‘HAS-REC’ and a second or more HAS episode 
significantly increase odds for death like in other studies 65, 79, 106, 107. Concerning adjusted risk for 
mortality in the HAS cohort, neonates with renal insufficiency or with a gastrointestinal disease needs 
our special attention. Organ failure, in particular renal failure, is a well-known consequence of severe 
sepsis as well in neonatal as in adult intensive care patients 108-112. Furthermore, another study also found 
that ‘necrotizing enterocolitis’ (the most frequent comorbidity of our gastrointestinal disease cohort) is 
an independent risk factor for mortality in infants with HAS 106.  
Limitations and recommendations 
Our study has limitations intrinsic to the retrospective and single-center design. Nevertheless, this single-
center study included a unique profile because of the homogenous standard of care applicable to both 
patients with and without HAS. In addition, data collection is based on a NICAUDIT system which used 
well defined risk factor definitions. Furthermore, certainty of HAS diagnosis was controlled by additional 
review of medical files. However, we cannot rule out that some patients with a HAS were not identified 
as such. Another limitation is the underpowered numbers of some included subgroups which might have 
biased some results (Type-I-error).  
Subsequent on previous research demonstrating that ‘gastrointestinal disease’ is a major risk factor for 
HAS, this study revealed that ‘HAS-REC’ in neonates with a gastrointestinal disease (mainly necrotizing 
enterocolitis) increased odds for mortality; also for neonates with a HAS, gastrointestinal disease might 
be a potential risk for mortality. As such, prevention initiatives for necrotizing enterocolitis and HAS are 
recommended. Future research might focus on factors affecting gut colonization with gram-negative 
pathogens, enhancement of the gastrointestinal barrier function, prevention of microbial translocation, 
and probiotic administration. It also might be interesting to explore the ‘gastrointestinal disease’ cohort 
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in a larger prospective research; as such, the impact of HAS-REC on mortality can be observed for several 
subgroups (for example, focal intestinal perforation, suspected-, definite-, advanced necrotizing 
enterocolitis). 
CONCLUSIONS 
In our NICU, HAS was not associated with mortality in the very low birth weight cohort most probably 
due to the high proportion of ‘HAS-COM’. Also, in very low birth weight neonates, underlying conditions 
might have overruled the impact of HAS on mortality. Furthermore, ‘HAS-REC’ may be an independent 
risk factor for mortality in heavier neonates and in neonates with a gastrointestinal disease; for the 
latter, most likely due to the high rate gram-negative causative pathogens. For this, our special attention 
is for infants with a gastrointestinal disease developing HAS-REC; prevention of HAS by means of 
infection prevention strategies for HAS and necrotizing enterocolitis is emphasized. For the HAS cohort, 
our results confirm the increased risk for mortality in infants with renal insufficiency or with a 
gastrointestinal disease.  
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Timely and accurate diagnosis of HABSI is crucial and challenging because of a time-consuming and 
imprecise blood culture test. For this, prediction models are the topic of interest in this chapter; 
prediction models for HABSI were systematically reviewed and a diagnostic accuracy analysis of these 
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Background and objectives: Blood culture is the gold standard to diagnose bloodstream infection but 
usually time-consuming. Prediction models aim to facilitate early preliminary diagnosis and treatment. 
We systematically reviewed prediction models for healthcare-associated bloodstream infection (HABSI) 
in neonates, identified superior models, and pooled clinical predictors. Data sources: LibHub, PubMed, 
Web of Science. 
Methods: The studies included designed prediction models for laboratory-confirmed HABSI or sepsis. 
Target population was a consecutive series of neonates with suspicion of sepsis hospitalized for ≥48 
hours. Clinical predictors had to be recorded at time of or before culturing. Methodological quality of the 
included studies was assessed. Data extracted included population characteristics, total suspected and 
laboratory-confirmed episodes and definition, clinical parameter definitions and odds ratios, diagnostic 
accuracy parameters. 
Results: The systematic search revealed 9 articles with 12 prediction models representing 1295 
suspected and 434 laboratory-confirmed sepsis episodes. Models exhibit moderate-good methodologic 
quality, large pretest probability range, and insufficient diagnostic accuracy. Random effects meta-
analysis showed that lethargy, pallor/mottling, total parenteral nutrition, lipid infusion, and postnatal 
corticosteroids were predictive for HABSI. Post hoc analysis with low-gestational-age neonates 
demonstrated that apnea/bradycardia, lethargy, pallor/mottling, and poor peripheral perfusion were 
predictive for HABSI. Limitations include clinical and statistical heterogeneity.  
Conclusions: Prediction models should be considered as guidance rather than an absolute indicator, 
since they all have limited diagnostic accuracy. Lethargy and pallor and/or mottling for all neonates as 
well as apnea and/or bradycardia and poor peripheral perfusion for very low birth weight neonates are 










INTRODUCTION   
Healthcare-associated bloodstream infection (HABSI) is the most frequent infectious complication in 
neonatal intensive care units (NICUs). Previous studies document incidence rates ranging from 5% to 
32%.10, 25, 35, 71 For neonates with very low birth weight (≤1500 g), the National Institute for Child Health 
and Human Development reported an incidence of 21% . HABSIs result in longer hospitalization (on 
average, +23 days) and a rise in mortality rate up to 24% for very low birth weight neonates.15, 18, 27-29 
Likewise, for pediatric and adult intensive care patients, HABSI is a common infectious complication.19, 37, 
72 Blood culture is the gold standard test to diagnose HABSI but prone to false-negative or false-positive 
results.44, 46, 113 Blood cultures positive for coagulase-negative staphylococci or other skin commensals 
might represent false-positive results due to contamination. Conversely, low blood culture volumes, 
which are a major issue in premature neonates, and previous antimicrobial therapy may be responsible 
for false-negative results.45, 46, 114 The test is not only imprecise but also time-consuming. Hence both in 
respect to diagnostic and therapeutic strategy, clinicians often must make preliminary decisions based 
on largely nonspecific signs, especially in very low birth weight neonates. Because of the possibly 
devastating consequences of HABSI, a low threshold for initiating antimicrobial therapy is generally 
accepted.47 Nonetheless, inadequate, inappropriate, or unnecessary empiric treatment can foster 
antimicrobial resistance, compromise gastrointestinal immunity and is associated with adverse 
outcomes.48, 50 In this context, prediction models with clinical parameters, in particular clinical signs, have 
been developed to facilitate preliminary sepsis diagnosis and the initiation of antimicrobial therapy.   
The first aim of this study was to systematically review prediction models for HABSI in hospitalized 
neonates and to evaluate their diagnostic accuracy to find superior models. The second aim was to pool 





A systematic literature review, diagnostic accuracy assessment of the prediction models, and random 
effects meta-analysis of clinical parameters were performed. The results are reported in accordance with 
the PRISMA guidelines (‘Preferred Reporting Items for Systematic Reviews and Meta-Analysis’ in 
Appendix 1).   
Literature search strategy   
A systematic search was done by 2 independent researchers (E.V., S.B.) on PubMed, LibHub, and Web of 
Science without language and time period restrictions (up to April 2014). After record screening based 
on abstract, language restrictions were applied. All keywords or Mesh terms were applied for [Title 
and/or Abstract] or [Topic] and contained four parts: (1) “bloodstream infection*” or “blood stream 
infection” or “sepsis” or “septic(a)emia*” or “bacter(a)emia*”; (2) “prediction model” or “diagnostic 
model” or “screening model” or “prediction score” or “screening score” or “diagnostic score” or 
“diagnostic markers” or “diagnostic tool” or “clinical markers” or “clinical signs” or “clinical 
characteristics” or “predictors”; (3) “neonate” or “newborn” or “preterm” or “neonatal” or “NICU”; (4) 
“healthcare(-)associated” or “hospital(-)acquired” or “nosocomial or late(-)onset”.  
Additional searches were performed by reviewing the bibliography of the retrieved full text articles and 
by a manual search of expert authors.  
Study selection criteria  
We included studies creating a prediction model for laboratory-confirmed HABSI with clinical signs. 
Laboratory-confirmed HABSI or sepsis was defined as a positive culture of blood, cerebrospinal fluid, 
pleural fluid, and/or urine; culturing was at least 48 hours after birth or admission. Target population 
was a consecutive series of hospitalized neonates with suspicion of sepsis. It was required that in these 
studies, relationships between clinical parameters and sepsis were assessed by univariate analyses 
whereas prediction models were developed by regression modeling; sensitivities, specificities, or ORs 
needed to be reported. Clinical parameters under research must be recorded preceding or at time of 
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culturing. The final prediction model needed to include at least 3 predictors; because neonatal sepsis is a 
complex clinical syndrome prediction models based on 2 possible parameters may not be justified. A 
checklist with all inclusion criteria was used to assess eligibility of the studies and when in doubt, issues 
for inclusion or exclusion were discussed between the 2 independent researchers. 
The following items were collected: population characteristics, setting, methods, statistical methods, 
exclusion criteria, applied case definition, definition for suspected HABSI/sepsis, total suspected 
episodes, total HABSI/sepsis episodes, assessment time of a suspected episode, clinical parameter 
definitions, predictor/event ratio, and prediction model accuracy. Model diagnostic accuracy was 
assessed by pre- and posttest probabilities, sensitivities, specificities, and positive and negative 
likelihood ratios.  
Quality assessment  
The Quality Assessment of Diagnostic Accuracy Studies-2 scale was used to evaluate the methodological 
quality of the included studies.115 This validated scale assesses criteria on 4 domains: patient selection 
(consecutive or random sampling, inappropriate exclusions, description of included patients), index test 
(description, execution, blinded interpretation), reference standard (accuracy, blinded interpretation), 
and flow and timing (application of and interval between reference standard and index test, exclusions 
for analysis). Because of limitations in quality scales, we also examined other individual components of 
methodological standards for prediction models: clearly defined outcome and predictive variables, 
description of patient characteristics, and cross validation.116-118 In addition, overfitting, which is a 
substantial threat in multivariate regression modelling, was assessed by calculation of the number of 
predictors included in the regression model per total events; this is termed as predictor/event ratio. 
Statistical methods  
74 
 
Comparisons between groups were performed using the Mann-Whitney U test for continuous variables 
and the Fischer exact test for categorical variables. The statistical package of social science version 21 
was used for these tests (SPSS Inc, Chicago, IL). 
A random effects meta-analysis using the inverse-variance method obtained ORs and 95% confidence 
interval (CI) for clinical predictors. This was performed by using the Comprehensive Meta-Analysis 
version 2 program (Biostat Inc, Englewood, NJ).  Statistical heterogeneity was predefined by using the 
Higgins I² statistic (I² ≤ 25% for low, 25% < I² < 50% for moderate, and I² ≥ 50% for high). Only those 
parameters that were similar in definition were pooled in order to avoid clinical heterogeneity. A 100% 
interobserver agreement (by E.V., K.B., S.B.) concerning these parameter definitions was required to be 
included in the random effects meta-analysis. Model diagnostic accuracy variables were calculated with 
a web-based diagnostic test calculator.119 
Funnel plots will be constructed for assessment of publication bias when at least 10 studies are included. 
RESULTS 
In total, 80 studies were retrieved of which 9 were included representing 12 prediction models or scores, 
a total of 1295 suspected and 434 laboratory-confirmed HABSI episodes. Figure 1 shows the results of 
the search strategy. Research period spanned from 1993 to 2007 with 3 West-European120-122, 4 South-
Asian123-126, 1 Canadian127, and 1 Turkish study128. All researches were performed in level III settings of 
which one126 was conducted in a low-resource level III hospital. 
Excluded studies not meeting inclusion criteria 
One study8 was excluded because the time-frame of recorded clinical parameters encompassed a 24-
hour follow-up postsepsis onset. Six studies developed a prediction model including early onset129-131 or 
community-acquired episodes of sepsis132-134. In several studies by Griffin et al.135-137 heart rate 
characteristics and clinical parameters are under study and prediction models are developed. However, 
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the studies of Griffin and colleagues as well as the research of Modi et al.56 considered all NICU patients 





Methodological quality of the included studies 
The methodological performance of the included studies could be considered as low-medium risk for 
bias. Patient selection was mostly well described as well as the motive for patient exclusion. Selected 
patients were all under suspicion of sepsis and were all prone to the reference test (ie, blood-, urine, or 
cerebrospinal fluid culturing) and an index test (ie, clinical prediction score or model). Index tests were 
overall well developed using similar statistical methods. The reference test blood culturing is considered 
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medium risk for bias because it is known not to be 100% accurate. Because of blood culture results are 
available only after at least 12 hours and index test performed before the blood culture test, the studies 
can be considered as double blinded, except for the 2 retrospective studies124, 128. Assessment of 
methodological standards for prediction models exhibited clearly defined outcome for all studies, 
moderate description of patient characteristics, and occasionally clearly defined clinical parameters. In 
particular, the definitions of the clinical signs and the interobserver variability in interpretation might be 
a medium risk for bias. Two studies122, 126 had no validation cohort but used a bootstrapping statistical 
technique for internal validation. Most studies defined the time of assessment as ‘day of sepsis workup’, 
so a timeframe for data collection of a maximum of 24 hours preceding sepsis workup is acknowledged. 
The 2006 retrospective study of Dalgic et al. did not describe the applicable timeframe for data 
collection. Concerning the issue of overfitting, the 2005 study of Okascharoen et al. overruled the 
generally accepted 1:10 predictor/event ratio, so this might be a risk for bias. A visual presentation rating 
the risk of bias in low, medium, and high is presented in appendix 2. 
General description of the included studies 
Characteristics of the 9 included articles are shown in table 1. Pretest probability of sepsis, defined as the 
number of lab-confirmed episodes per total suspected episodes, ranged between 17% to 55%, indicating 
an important variation in study population. Three studies did not include all neonates with suspicion of 
sepsis in their research; selection was made for neonates with gestational age <34 weeks122, 126 and for 
birth weight ≥1000g and ≤2500g125. One study128 did not report information on patient characteristics 
but did focus on nosocomial sepsis in neonates on neonatal intensive care. Two studies were internal127 
and external validation studies121 of their former developed prediction score study. Another 2 studies125, 





Table 1. Characteristics of the nine included articles              
Study 
(year) 















PRO/               Internal/        Number   











Extra criteria for BC with skin 
commensal: 2 positive BC from 2 




















Positive BC  
Extra criteria for BC with skin 
commensal: 2 positive BC from 2 
venipunctures  
or at least 1 from CVC 
None No  
regression 
modelling 
BC not drawn before  
starting antibiotics 
Internal and external validation study  of Mahieu et al.23 
and testing of NOSEP-new-I and NOSEP-new-II which 











Positive BC or CSF culture 16 CS 7/105 Major CM 
>28 Days of life 
PRO Internal 220 
Okascharoen31 
(2005) 











Bacteria in blood, CSF, pleural fluid, 
bone joint,  
or urine >10⁵CFU/mL 
Extra criteria for BC with skin 
commensal: 2 positive BC from 2 
punctures on the same day  
8 CS 
5 BM  
17 RF 
20/100 Life-threatening CM                        
Suspicion of late onset 
sepsis started within 7 days 
after ceasing antibiotics for 
early onset sepsis 
A 2nd or more episode 













Positive BC None  No  
regression 
modelling 
No data External validation of Mahieu et al.23 and testing of a 











Positive BC or CSF culture 
Contamination is defined as ignoring 
of a positive BC by the attending 
clinician and discontinuation of  
antibiotic therapy. 
None No  
regression 
modelling 
BC not drawn before  
starting antibiotics 
Previously discharged home  
>28 days of life 










Clinical suspicion of sepsis along with 





Died <24h after onset of 
illness 
External validation of Singh et al.26 and testing a 
combined model with sepsis screen and clinical score 
with no internal or external validation 
Rosenberg33 
(2010) 











21 CS 21/193 Major CM 
> 72h postnatal age before 
admission 
BC drawn < 4 days apart in 
same infant 
> 28 days of life 
External validation of Sing et al.26 and development of 















BC with skin commensal: 2 positive 
BC and/or signs of catheter-related 
bloodstream infection, ie. 
inflammation at insertion site 
14 CS 
7 RF 
6/187 Antibiotics 24h before  
assessment time 
No validation cohort 
BC, blood culture; BM, biological markers; CM, congenital malformation; CVC, central vascular catheter, CS, clinical signs; CSF, cerebrospinal fluid; PRO, prospective; RETRO, retrospective; RF, risk factors 
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Table 2. Characteristics of 12 prediction models   





Model variables  Score Model 
applica- 
Tion 

























Neutrophil fraction >50%  

















































NOSEP 2 NOSEP 1+ positive hub-  
and exit site cultures 
 Score of 
≥11 +  
positive  
culture 









Neutrophil fraction >63%  




























NOSEP new-1 + recent 
surgery+ maternal 
hypertension + ventilation  
 Score of 
≥11 + 3 risk 
Factors 





score for  
definite 
sepsis 
Abdominal distention  
Chest retraction  
Grunting  
Hyperthermia  

















































Abnormal body temperature  
Hypotension   
Neutrophil bandemia ≥1% 
Respiratory insufficiency   
Thrombocytopenia 
<150x10³/μL  
Umbilical line ≤7days 









































































Score of  























Abdominal distention;  
chest retractions; grunting; 
hyperthermia; lethargy; 

































Absolute neutrophil count; 




No score ≥2 markers 27 48 70 37 21 1.60 0.74 No data 
Clinical 
score  + 
sepsis 
screen 
Abdominal distention; chest 
retractions; grunting; 
hyperthermia; lethargy; 
tachycardia; pre feed 
aspirates; absolute neutrophil 
count; CRP; micro  
erythrocyte sedimentation 
rate; neutrophil ratio  
No score ≥1 clinical 
sign +  
≥2 markers 












































Capillary refill > 2s 
Central line in last  24h 
Increased respiratory support 
Lethargy 
No score 1 of the 4 
signs 
27 97 37 36 3 1.54 0.08 0.83 (0.06) 
CRP, C-reactive protein; LR+ or -, likelihood ratio of a positive or negative test; NOSEP, nosocomial sepsis score; ROC, receiver operating characteristic; SE, standard error; TP, test 






Characteristics and diagnostic accuracy of the prediction models 
Characteristics and diagnostic accuracy of the 12 prediction models with several cutoff scores are 
tabulated in Table 2. It is observed that 3 models with a particular cutoff score have a sensitivity of at 
least 95%. Of these 3 models, Mahieu et al’s nosocomial sepsis score (NOSEP), with a point score of 8 or 
higher, displays the highest specificity and positive likelihood ratio.  Figure 2 is a visual comparison of the 
sensitivity and specificity of 7 models. If a model has several cutoff scores, it is represented with its 
highest sensitivity model. 
Random effects meta-analysis 
Odds ratios of clinical parameters in univariate analysis of 5 studies120, 122-124, 126 were included in the 
random effects meta-analysis. Ten of the 29 clinical signs and 8 of the 22 risk factors within 2 to 5 studies 
could be pooled. Eleven clinical signs and 12 risk factors were research variables in 1 study; another 6 
clinical signs and 2 risk factors could not be pooled due to heterogeneity in variable definition. 
Definitions of the pooled and nonpooled clinical signs and risk factors are presented in appendix 3. 
Cutoff values of biological markers were largely different, and data on laboratory techniques used were 
not available, so biological markers were not pooled. Pooled OR and statistical heterogeneity of all 18 
individual clinical parameters are tabulated in Table 3. Figure 3 displays the forest plots of the 5 
significant clinical parameters predictive for HABSI in neonates. Because 10 of 18 clinical parameters 
exposed medium to high statistical heterogeneity, a pos hoc analysis was performed with 2 studies122, 126 
including solely low gestational age neonates (<34 weeks) and 9 clinical signs. Pooled OR and statistical 
heterogeneity of these 9 signs are tabulated in Table 4. Figure 4 displays the forest plots of the 4 






Table 3. Pooled odds ratios and statistical heterogeneity of clinical parameters predictive for healthcare- 
associated bloodstream infections in all studies. 
 
Table 4. Pooled odds ratios and statistical heterogeneity of clinical sings predictive for healthcare-associated 













Apnea/Bradycardia 1.60 0.78-3.30 0.20 69.0% 5/579 
Distended abdomen 1.30 0.80-2.12 0.29 0.0% 4/437 
Feeding intolerance 1.40 0.64-3.03 0.40 55.0% 5/579 
Fever 1.72 0.86-3.45 0.13 37.0% 3/302 
Grunting 1.02 0.54-1.93 0.94 0.0% 4/479 
Hypothermia 1.78 0.85-3.74 0.13 0.0% 3/302 
Lethargy 3.98 1.69-9.40 0.002 72.0% 4/499 
Pallor/Mottling 2.55 1.26-5.18 0.010 52.0% 3/419 
Tachycardia 1.64 0.96-2.79 0.07 5.0% 3/399 
Tachypnea 1.27 0.68-2.34 0.45 29.0% 3/399 




Bronchopulmonary dysplasia 5.17 0.33-81.30 0.24 79% 2/180 
Lipid infusion 4.17 1.85-9.40 0.001 0% 2/180 
Male gender 1.27 0.72-0.23 0.41 0.0% 2/242 
Necrotizing enterocolitis 2.59 0.38-17.50 0.33 42% 2/180 
Postnatal corticosteroids 3.77 1.08-13.18 0.04 21% 2/180 
Total parenteral nutrition  3.60 1.68-7.69 0.001 0% 2/180 
Ventilation  1.32 0.43-4.02 0.63 70.0% 3/322 
Very-low-birth weight 2.90 0.36-23.60 0.99 87% 2/180 
Predictor: clinical signs Pooled 
OR 




Apnea/Bradycardia 1.66 1.06-2.61 0.028 0.0% 2/319 
Feeding intolerance 1.15 0.70-1.89 0.59 0.0% 2/319 
Grunting 0.88 0.43-1.80 0.72 0.0% 2/319 
Irritability 0.88 0.38-2.04 0.77 0.0% 2/319 
Lethargy 4.25 2.50-7.21 <0.001 0.0% 2/319 
Pallor 2.04 1.31-3.20 0.002 0.0% 2/319 
Poor peripheral perfusion 2.68 1.54-4.66 <0.001 0.0% 2/319 
Tachycardia 1.33 0.48-3.70 0.58 50.0% 2/319 




A. Lethary B. Pallor/mottling 
  
C. Lipid infusion D. Total parenteral nutrition 
  
E. Postnatal corticosteroids 
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To our knowledge, this is the first systematic review of clinical prediction models for HABSI in neonates. 
Three prediction models have a sensitivity of at least 95%, but lack further diagnostic accuracy. Lethargy 
and pallor and/or mottling appear to be the best predictive clinical signs whereas the use of total 
parenteral nutrition (TPN), lipid infusion, and postnatal corticosteroids are significant iatrogenic risk 
factors that should strengthen suspicion for HABSI when clinical signs occur.  
The strengths of this study include methodologic quality and diagnostic accuracy evaluation of the 
models and a random effects meta-analysis design.  
Diagnostic accuracy of the prediction models 
The variables of the included prediction models were largely different, so diagnostic test accuracy meta-
analysis had no clinical connotation and was not executed. Considering diagnostic accuracy, pre- and 
posttest probability, sensitivity, specificity, and positive and negative likelihood ratios were assessed. 
First, a large range in pretest probability was detected, reflecting a fundamental variation in clinical 
condition of the study population and influencing the posttest probability results. In addition, some 
models exhibit minor progress when comparing pre- and posttest probability (range of progress, 3%-
59%); major improvement (>50%) is noted for the NOSEP score of 14 and the bedside prediction score of 
6, although the latter experienced a low pretest probability. Mahieu et al’s 2 NOSEP score models, which 
have high pretest probability, have shown a good pre- to posttest probability progress, which might 
indicate effectiveness. Second, diagnostic performance is a major concern. It is observed that only 3 
models have sufficient sensitivity. A sensitivity of at least 95% is required for a potentially lethal 
condition such as HABSI. The NOSEP score of 8 of Mahieu et al.120, the clinical score (1sign) and sepsis 
screen (2 biomarkers) of Kudawla et al.125, and the reduced model (1 sign) of Bekhof et al.122 exhibit 5% 
or less false-negative cases. In contrast, the specificity of these 3 models is low (range, 18%-43%); of 
these 3, the NOSEP score of 8 reports the highest specificity (43%), nonetheless indicating  33.7% false-
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positive cases (n=35) and only a 1.67 chance on a positive test for cases versus noncases. However, when 
clinical deterioration is a criterion for culturing, those 33.7% false-positive cases might be considered 
true-positive cases for another illness, justifying antimicrobial therapy. In contrast, when a C-reactive 
protein of 1mg/dL is a criterion for culturing and a NOSEP score of 8 is detected, the clinical condition of 
the neonate might not yet be taken into consideration; for example, a neonate receiving TPN ≥14 days 
with a neutrophil fraction >50% has a NOSEP score of 9. In this case, the score can indicate close 
monitoring of the neonate and increased or more frequent observation of clinical signs. Clinically, 
antibiotic treatment might be postponed until clinical deterioration or a score of 11 is reached so that 
overtreatment can be repressed.52, 98  
Overall, prediction models have been developed to streamline the plethora of signs and risks for HABSI 
and thus to facilitate medical judgment and decision-making concerning treatment. In clinical practice, 
the interpretation of the nonspecific clinical signs is pivotal, although not always obvious and subject to 
interobserver variability. The consistency with other symptoms as well as underlying conditions must be 
considered. Important here is the weight assigned to a clinical observation. It is not only the presence of 
a clinical sign but primarily a change in the presentation of that clinical sign that might lead to accurate 
prediction of HABSI.56, 138, 139 For example, premature neonates have more respiratory distress than full-
term neonates, so signs such as apnea, chest retraction, and grunting might be less appropriate to 
predict HABSI. However, when a sign is defined as ‘an increase of’ or ‘acute onset of’ the clinical 
relevance is emphasized. Suggestions for risk stratification based on setting, birth weight or gestational 
age could also be considered in this context.22, 82, 140, 141  
Random effect meta-analysis  
Lethargy and pallor and/or mottling are significant clinical signs predictive for HABSI (P < 0.050) and are 
observed with a high statistical heterogeneity of ≥50.0%; post hoc analysis with low gestational age 
neonates revealed a reduction to 0% thus heterogeneity might be caused by clinical differences. Caution 
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is warranted in interpretation regarding post hoc analysis, but omitting the results of Okascharoen et 
al.124, which showed the strongest association for lethargy and pallor/mottling, can also be interpreted as 
a sensitivity analysis. Therefore, it is likely that our results are reliable. Lethargy is often found to be 
associated with sepsis for all neonates, including low gestational age or very low birth weight neonates.8, 
56, 137, 142, 143 Regarding pallor and/or mottling, several studies included pallor and/or mottling in their 
research. One study144, which included all neonates, could not find a significant association between 
pallor and sepsis. Another multicenter study56, which included very low gestational age neonates, 
clustered pallor and/or mottling under impaired peripheral perfusion. In this study, impaired peripheral 
perfusion was a strong predictor for a positive blood culture (OR 8.5, CI 5.4–13.2). In the study of Ohlin 
et al.140 pallor/mottling was clustered with hypotension, and a significant association was found (OR 
2.47, CI 1.48–4.14). Van den Bruel et al.145 systematically reviewed clinical signs and their diagnostic 
value in ambulatory care settings for children aged 1 month to 18 years. They described impaired 
peripheral perfusion resulting in pallor/mottling and lethargy/reduced consciousness as red flags in the 
detection of serious infection. Additionally, convulsions, rapid breathing, and cyanosis were strongly 
associated with serious infection.  
Concerning risk factors, TPN, lipid infusion, and postnatal corticosteroid administration were significant 
after pooling. TPN and lipid infusion are generally accepted as important risk factors, particularly for 
HABSIs caused by coagulase-negative Staphylococcus.36, 74, 82-85 Interestingly, in our analysis, very low 
birth weight was not a significant predictor despite being associated with HABSI in many studies.10, 36, 73 
The pooled very low birth weight OR involved 2 studies, Okascharoen et al.124 (unadjusted OR 9.1, CI 
[3.0-26.5]) and Mahieu et al.120  (unadjusted OR 1.1, CI [0.5-2.4]) representing 180 neonates, 60 of whom 
had laboratory-confirmed HABSI. The lack of power might be a concern here.   
Limitations and recommendations 
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Although a systematic search was done by 2 independent researchers, incomplete retrieval of studies, as 
well as publication bias and heterogeneity, might influence our results.  
Concerning the power of the random effects meta-analysis, some pooled parameters are based on <200 
suspected cases or <100 laboratory-confirmed cases.  For future research, it might be interesting to 
include all studies in which the objective was to find clinical parameters predictive for HABSI or 
nosocomial sepsis by univariate analysis. As such, power of the pooled results will increase.  
In the past decade, much research has considered heart rate characteristics as an early diagnostic sign 
for neonatal sepsis.146-150 Including an index of heart rate characteristics in a prediction model for 
neonatal sepsis seems promising.146, 148, 151, 152  
Different characteristics of the neonatal population in various settings are not always reported; this may 
lead to concerns with external validity of the prediction models. The addition of clinical parameters 
related to specific neonatal services and subgroups is recommended for future work.  
Furthermore, future models might potentially benefit from bedside technology capable of quantifying 
subjective symptoms. For example, pallor and/or mottling could be replaced by continuous monitoring 
of peripheral microcirculation, and lethargy could be measured by continuous functional monitoring of 
brain activity. 
CONCLUSION 
A prediction model should be considered as guidance rather than an absolute indicator because all 
models have limited diagnostic accuracy. However, the use of prediction models might decrease the use 
of antimicrobial therapy. In clinical practice, the NOSEP score of 8 or more by Mahieu et al.120 has the 
greatest potential but may necessitate additional consideration of the patient’s clinical condition, 
depending on the criteria for culturing in a given setting. Furthermore, these findings suggest that 
lethargy and pallor and/or mottling for all neonates and apnea and/or bradycardia and poor peripheral 
perfusion for very low birth weight neonates are the most powerful clinical signs in the prediction of 
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HABSI. Nonetheless, other clinical signs should not be discarded. As stated earlier, the particular clinical 
context should always be taken into account.  
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Mahieu 
(2002) 
           NA   NA 
Singh 
(2003) 
               
Okascharoen 
(2005) 
               
Dalgic 
(2006) 
           NA   NA 
Okascharoen 
(2007) 
           NA  NA NA 
Kudawla 
(2008) 
           NA   NA 
Rosenberg 
(2010) 
               
Bekhof 
(2013) 
               
NA, not applicable; green, low risk ; yellow, medium risk; red, high risk. 
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Appendix 3. Pooled and non-pooled clinical parameter definitions  
 
Pooled clinical signs Study Variable definition 
Apnea/Bradycardia Bekhof et al. 2013 
Mahieu et al. 2000 
Okascharoen et al. 2005 
Rosenberg et al. 2010 
Singh et al. 2003 
Increasing frequency of apnea, bradycardia, and/or cyanotic spells 
Apnea 
Apnea, bradycardia, cyanosis, tachypnea 
Cessation of breathing>20s or with cyanosis, bradycardia or limpness 
Cessation of breathing>20s or with cyanosis, bradycardia or limpness 
Distended abdomen Mahieu et al. 2000 
Okascharoen et al. 2005 
Rosenberg et al. 2010 
Singh et al. 2003 
Abdomen distention and/or guanic stools 
Not defined 
Distention by 2cm 
Distention by 2cm 
Feeding intolerance Bekhof et al. 2013 
Mahieu et al. 2000 
Okascharoen et al. 2005 
Rosenberg et al. 2010 
Singh et al. 2003 




Non-acceptance of feeds despite being awake at a scheduled feed 
time 
Fever Bekhof et al. 2013 
Mahieu et al. 2000 




Grunting Bekhof et al. 2013 
Rosenberg et al. 2010 
Singh et al. 2003 
Grunting and/or nasal flaring and/or chest retraction 
Audible expiratory sound 
Audible expiratory sound 
Hypothermia Bekhof et al. 2013 
Mahieu et al. 2000 




Irritability Bekhof et al. 2013 
Rosenberg et al. 2010 
Not defined 
Not defined 
Lethargy Bekhof et al. 2013 
Okascharoen et al. 2005 
Rosenberg et al. 2010 
Singh et al. 2003 
Not defined 
Not defined 
Persistent difficulty in arousing while off sedative medication 
Persistent difficulty in arousing while off sedative medication 
Pallor/Mottling Bekhof et al. 2013 
Okascharoen et al. 2005 
Rosenberg et al. 2010 
Pallor and/or grey skin 
Pallor and/or mottling 
Pallor 
Poor peripheral perfusion Bekhof et al. 2013 
Rosenberg et al. 2010 
Capillary refill of >2s 
Poor peripheral perfusion 
Tachycardia Bekhof et al. 2013 
Rosenberg et al. 2010 
Singh et al. 2003 
Not defined 
Heart rate >160/min 
Heart rate >160/min 
Tachypnea Bekhof et al. 2013 
Rosenberg et al. 2010 
Singh et al. 2003 
Not defined 
Respiratory rate >60/min 
Respiratory rate >60/min 
Non-pooled clinical signs Study Variable definition 
Chest retraction Singh et al., 2003 In drawing of ribs with each inspiration 
CVC exit site  Mahieu et al., 2000 Swelling, redness or pus 
Cyanosis Rosenberg et al., 2010 
Singh et al., 2003 
Not defined 
Central cyanosis: oxygen saturation of <80% 
Dyspnea Bekhof et al., 2013 Not defined 
Hepatomegaly  Rosenberg et al., 2010 Not defined 
Hypotension Mahieu et al., 2000 
Okascharoen et al., 2005 
Acidosis or hypotension not defined 
Not defined 
Increased aspirates Singh et al., 2003 Increased pre-feed gastric aspirates of >20% 
Inflammation Rosenberg et al., 2010 Local inflammation 
Jaundice Rosenberg et al. , 2010 Not defined 
Not looking well Singh et al., 2003 Subjective assessment by nurse or doctor 
Petechiae  Rosenberg et al., 2010 Not defined 








Appendix 3. Pooled and non-pooled clinical parameter definitions (continued). 
Respiratory distress Bekhof et al., 2013 
Bekhof et al., 2013 
Mahieu et al., 2000 
Mahieu et al., 2000 
Okascharoen et al., 2005 
Rosenberg et al., 2010 
Increased need for oxygen 
Increased respiratory support 
Oxygen requirement 
Ventilation requirement 
Respiratory insufficiency  
Not defined 
Sclerema Rosenberg et al., 2010 
Singh et al., 2003 
Not defined 
Diffuse non-pitting skin thickening that cannot be pinched 
Seizure Rosenberg et al., 2010 
Singh et al., 2003 
Not defined 
Repetitive stereotyped non-suppressible motor movements 
Splenomegaly Rosenberg et al., 2010 Not defined 
Temperature instability Bekhof et al., 2013 
Mahieu et al., 2000 
Okascharoen et al., 2005 
Not defined 
Several cut-off values 
Abnormal body temperature: hypothermia, hyperthermia or 
temperature instability 
Vomiting Rosenberg et al., 2010 Not defined 
Pooled risk factors  Study Variable definition 
Bronchopulmonary dysplasia Mahieu et al., 2000 
Okascharoen et al., 2005 
Not defined 
Not defined 
Lipid infusion Mahieu et al., 2000 
Okascharoen et al., 2005 
Not defined 
Not defined 
Male gender Bekhof et al., 2013 
Okascharoen et al., 2005 
No need for definition 
No need for definition 
Necrotizing enterocolitis Mahieu et al., 2000 
Okascharoen et al., 2005 
Not defined 
Not defined 
Postnatal corticosteroids Mahieu et al., 2000 
Okascharoen et al., 2005 
Not defined 
Not defined 
Total parenteral nutrition  Mahieu et al., 2000 
Okascharoen et al., 2005 
Not defined 
Parenteral nutrition therapy 
Ventilation  Bekhof et al., 2013 
Mahieu et al., 2000 
Okascharoen et al., 2005 
On mechanical ventilation 
On ventilation 
On ventilation support 
Very-low-birth weight Mahieu et al., 2000 
Okascharoen et al., 2005 
≤1500 gram 
≤1500 gram 
Non-pooled risk factors Study Variable definition 
Age at episode  Bekhof et al., 2013 Age at episode in days 
Birth weight Bekhof et al., 2013 Birth weight per 100gram 
Congenital malformation Okascharoen et al., 2005 Major congenital anomalies 
CVC  Bekhof et al., 2013 
Mahieu et al., 2000 
Mahieu et al., 2000 
Mahieu et al., 2000 
Mahieu et al., 2000 
Mahieu et al., 2000 
Okascharoen et al., 2005 
Okascharoen et al. , 2005 
In the last 24h 
Duration of CVC ≥8 days  
Duration of CVC ≥15 days 
Non-umbilical CVC  
Umbilical CVC  
Umbilical CVC >7 days 
Umbilical arterial catheterization  
Umbilical venous catheterization  
Delivery Okascharoen et al., 2005 Assisted or caesarean  
Ductus arteriosus Okascharoen et al., 2005 Patent ductus arteriosus 
Foreign body Mahieu et al., 2000 Not defined 
Gestational age Bekhof et al., 2013 
Mahieu et al., 2000 
Okascharoen et al., 2005 
Gestational age per week 
<37 weeks 
≤34 weeks 
Multiple pregnancy Okascharoen et al., 2005 Not defined 
Prenatal corticosteroids Okascharoen et al., 2005 Prenatal corticosteroids  
PVC Okascharoen et al., 2005 Not defined 
TPN duration Mahieu et al., 2000 Several cut-off values in days 
Recent surgery Mahieu et al., 2000 Not defined 
Weight at episode  Bekhof et al., 2013 Weight at episode in gram 
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For validation of our retrospective results and for the examination of blood culture sampling practice, a 
prospective multicenter research was instigated. This chapter describes and discusses the results of the 
prospective study: sampling frequencies, clinical indications for sampling, antimicrobial therapy 
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Objective: Healthcare-associated sepsis (HAS) is a frequent complication in neonatal intensive care units 
(NICUs) and blood culturing is one of the most commonly executed diagnostic procedure. We aim to 
describe blood culturing frequencies, clinical indications, and the initiation of antimicrobial therapy (ABT) 
in suspicion of healthcare-associated sepsis (HAS), and to evaluate which clinical indications and risk 
factors are associated with HAS. Additionally, we developed a sepsis indication model. 
Design: Prospective multicenter cohort study.  
Setting: Three tertiary referral NICUs.  
Patients: A consecutive series of HAS-suspected newborns hospitalized in the NICU for ≥48 hours (period 
July 2013-December 2014).  
Interventions: Ten predefined clinical signs, NOSEP score, C-reactive protein, ABT initiation, and risk 
factors were registered at time of blood culturing; logistic regression analysis was executed to determine 
the association with lab-confirmed HAS. The predictive performance of the sepsis indication model was 
determined by area-under-the-receiver-operator-characteristic-curve (AUC) analysis. 
Measurements and Main Results: Two-hundred-ninety-nine suspected HAS-episodes were considered in 
212 infants, of which 118 had birth-weight ≤1500 g. Median CRP and number of clinical signs per episode 
was significantly different between centers (respectively 11 mg/L vs. 5 mg/L vs. 3 mg/L, P =.001; 1-sign 
[center-1] vs. 3-signs [center-2 and -3], P <.001). Significant difference in initiation of ABT was noticed 
between centers (82% vs. 93% vs. 74%, P =.048). A sepsis indication model was developed: ‘occurrence-
of-two-clinical-signs’ (adjusted odds ratio [aOR] 2.6, confidence interval [CI] 1.4-4.7), ‘mechanical 
ventilation’ (aOR 2.5, CI 1.3-4.8), and ‘peripherally-inserted central catheter’ (aOR 1.8, CI 1.0-3.2) were 
independently associated with ‘lab-confirmed sepsis’, though predictive performance of this model is 
weak (AUC 0.67, CI 0.59-0.74). Predictive performance of this model for ‘lab-confirmed and/or clinical 
sepsis’ as outcome was good (AUC 0.84, CI 0.79-0.89).  
Conclusions: Center heterogeneity in sampling practice is substantial. Optimizing sampling practice and 








Healthcare-associated sepsis (HAS, occurring >48 hours after birth) is the most frequent infectious 
complication in neonatal intensive care with substantial risk for neurological sequelae and mortality.10, 27, 
28, 35, 71 Blood culture test in the gold standard for sepsis diagnosis and is one of the most commonly 
executed diagnostic procedure in infants admitted to a neonatal intensive care unit (NICU). The majority 
of the blood cultures are sampled on the day of birth and approximately 40% are sampled in suspicion of 
HAS.153 Guidelines on clinical indications for blood culturing in neonates suspected for HAS are lacking so 
various thresholds for are assumed. Moreover, due to the potential severity and lethality of HAS, a low 
threshold for blood culture sampling and antimicrobial therapy (ABT) initiation is accepted.154 In 
addition, the ‘gold standard’ blood culture test is time-consuming and imprecise so early and correct 
diagnosis of HAS is challenging and mostly based on clinical judgement of nonspecific clinical signs and 
inflammatory biomarkers.44, 46, 113 Much attention is for the predictive value of biomarkers such as C-
reactive protein (CRP), procalcitonin, anti-inflammatory cytokines. However, those biomarkers can be of 
noninfectious origin, have limited diagnostic accuracy and may not have the ability to differentiate 
between several inflammation sources.131, 155-157  Likewise for clinical signs, which are mostly subtle and 
difficult to interpret, predictive value is questionable.158 Since single parameters are unspecific, there is 
need for an integrated approach. For this and because of the assumption of different threshold for 
sampling, we aim to assess sampling practice in 3 NICUs; we will describe blood culture sampling 
frequencies, clinical indications, and ABT administration. In addition, a sepsis indication model will be 
developed and its diagnostic accuracy will be calculated.   
METHODS 
Study design and Patient population 
We performed a multicenter prospective cohort study. All neonates admitted to the NICU of 3 Belgian 
tertiary referral hospitals for ≥48 hours were eligible for inclusion. During an 18-months study period 
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(July 2013-December 2014) a consecutive series of blood culture samples of neonates under suspicion of 
HAS were included; blood cultures sampled within 7 days of each other and after the initiation of 
antimicrobial therapy were excluded. The outcome of a suspected episode was classified in ‘lab-
confirmed sepsis’, ‘clinical sepsis’, or ‘no sepsis’. Classification was made by the principal investigator 
(E.V.) according to the Neo-KISS criteria26. 
Ghent University Hospital (center-1) and University Hospital of Antwerp (center-2) are academic centers 
with respectively a 32-bed and 28-bed NICU. General Hospital Saint-Jean of Bruges (center-3) is a non-
academic center with a 32-bed NICU. The yearly mean admission rate of center-1 is approximately 550 of 
which circa 18% are very low birth weight neonates (ie. 1500 g or less); neonatal specialist services 
include pediatric cardiology and cardiac surgery. For center-2 and center-3, the yearly admission rate is 
respectively approximately 400 and 470 of which 25% and 15% are very low birth weight. Only newborn 
infants (ie., less than 28 days of life) are admitted to these units.  
The study was approved by the Ethics Committee of the participating centers. 
Data collection 
Prospective registration of 10 predefined clinical signs, CRP, and antimicrobial therapy initiation was 
completed by the attending neonatologist using standardized sticker labels (appendix 1); assessment of 
the clinical signs and CRP was at time of sampling and for clinical signs encompasses an interpretation 
period of maximum 24 hours before sampling. Blood cultures were sampled by venipuncture or from a 
newly inserted central line, volume was standardized at 1 mL; skin or catheter-hub disinfection time was 
standardized at 30s (protocol in appendix 2). In all centers blood cultures were assessed using the 
BacT/Alert 3D automated microbial detection system (bioMérieux Inc., Durham, NC). The 10 predefined 
clinical signs suggestive for sepsis56 were increased or acute onset of: ‘tachypnea/oxygen need’; 
‘apnea/bradycardia’; ‘hypotension’ (<40 mmHg or <35mmHg systolic plus additional oliguria for 
neonates weighing >1500g or ≤1500g respectively); ‘glucose intolerance’ (2 subsequent values of >150 
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mg/dl); ‘impaired peripheral perfusion’ (capillary refill time of >3s, pallor or mottling, core-peripheral 
temperature gap >2°C); ‘lethargy’; ‘temperature instability’ (<36°C or >38°C), ‘ileus’ (distended abdomen 
included) or ‘feeding intolerance’ (>10% residual),  ‘oliguria’ (<1 ml/kg/h), ‘base-deficit’ (<-10 mmol/L). 
Other recorded clinical signs were: ‘convulsions’ (n = 2), ‘sweaty’ (n = 2), ‘inflammation/oedema around 
catheter insertion’ (n = 2), ‘instable saturation’ (n = 2), ‘heart rate instability’ (n = 2), hyperinsulinemia (n 
= 1), ‘hypoglycemia’ (n = 1), and ‘tachycardia’ (n = 3). Also, registration forms were completed by the 
principal investigator with following additional characteristics and risk factors: ‘date of admission’, ‘date 
of birth’, ‘gender’, ‘birth weight’, ‘gestational age’, ’intra-uterine growth restriction’ (IUGR), plus 
‘catheterized’ (peripheral, arterial, umbilical, surgical, or peripherally-inserted central catheter [PICC]), 
‘TPN days’, and ‘mechanical ventilation’ for at least 24 hours before culturing, ‘recent major surgery’ 
maximum 7 days before culturing, ‘postnatal steroid administration’ before culturing, ‘pathogen’, ‘days 
of antibiotics’, ‘other infection’, ‘length to stay’, and NOSEP-score120 (including CRP ≥14 mg/L, neutrophil 
fraction >50%, temperature >38.2°C, total parenteral nutrition [TPN] ≥14days, thrombocytopenia 
<150x10³/μL) (appendix 3). In center-2, sampling was indicated when a NOSEP-score value ≥8 was 
attained. 
Definitions and classification 
Healthcare-associated sepsis occurs at least 48 hours after birth and is defined as ‘lab-confirmed’ when a 
pathogen was detected in a blood culture.1 Positive additional urine and cerebrospinal fluid cultures and 
X-ray-confirmed ventilator associated pneumonia and necrotizing enterocolitis were also defined as ‘lab-
confirmed sepsis’. When the causative pathogen is a skin commensal,  mainly coagulase-negative 
staphylococci or viridans group streptococci, additional criteria are needed: 2 clinical signs and a CRP of 
>20 mg/L.26 ‘Clinical sepsis’ is defined as the presence of 2 clinical signs and the initiation of antimicrobial 
therapy of at least 5 days when no pathogen was detected in blood culture and no apparent other site of 
infection is assumed. 26 Blood cultures positive for skin commensals not meeting the criteria for lab-
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confirmed but meeting criteria for clinical sepsis were categorized as ‘clinical sepsis’; when not meeting 
the criteria for clinical sepsis blood cultures were considered ‘contaminated’ and classified as ‘no sepsis’. 
Statistics 
Logistic regression analysis was used to determine the association between the clinical indications or risk 
factors and ‘lab-confirmed sepsis’ (‘no sepsis’ and ‘clinical sepsis’ as controls); the association of patient-
specific risk factors, ie. ‘birth weight’, ‘gestational age’, ‘gender’, and ‘IUGR’, was only evaluated for the 
first suspected HAS episode. Unadjusted odds ratios (ORs) and 95% confidence intervals (CI) were 
calculated and when P <0.20 or when considered clinically relevant included in regression modeling 
(except for NOSEP-score value ≥8). For model development, a stepwise selection technique was used 
with ‘enter’ method; highest P values were rejected in a stepwise manner; two-tailed P values < 0.10 
were retained. Predictive performance was calculated by sensitivity, specificity, positive- and negative-
predictive value, area-under-the-receiver-operator-characteristic-curve (AUC), and Hosmer-Lemeshow 
goodness-of-fit-test. Because of our aim, developing a sepsis indication model, predictive performance is 
calculated for ‘lab-confirmed sepsis’ (‘no sepsis’ and ‘clinical sepsis’ as control group) and for ‘lab-
confirmed and/or clinical sepsis’ (‘no sepsis’ as control group). The statistical package of social science 
version 21 was utilized for all tests (SPSS Inc, Chicago, IL).   
RESULTS 
Cohort description  
A total of 413 blood culture samples in 301 neonates were registered. Of these 413 samples, 95 were 
excluded because of prior antibiotic administration and an additional 19 because of a repeated blood 
culture within 7 days. For final analysis, 299 separate blood culture samples in 212 neonates were 
included of which 118 (55.7%) had birth weight ≤1500 g; median birth weight, gestational age, and  





PICC, peripherally-inserted central catheter; °Kruskal-Wallis test; *Fischer’s Exact test. 
 
TABLE 2. Pathogen Distribution of 35 Lab-confirmed Bloodstream and Urine Tract Infection Episodes 
Pathogens Total  
(N=40) 
 
Total gram-positive pathogens, n (%) 26 (65)  
    Bacillus spp.  1 (3)  
    Coagulase-negative staphylococci 7 (18)*  
    Staphylococcus aureus 15 (38)  
    Enterococcus spp. 1 (3)°  
    Group B Streptococcus spp. 2 (5)  
Total gram-negative pathogens, n (%) 13 (33)  
    Acenitobacter spp.  1 (3)  
    Citrobacter spp.  1 (3)  
    Escherichia coli 7 (18)  
    Enterobacter spp. 2 (5)  
    Klebsiella spp. 1 (3)  
   Serratia spp. 1 (3)  
Candida spp., n (%) 1 (3) 
 














P  Value 
Birth weight, median (IQR) 









Gestational age, median (IQR) 32 (28-36) 27 (26-31) 30 (28-32) <.001° 
Intra-uterine growth restriction, n (%) 19 (14) 3 (7) 2 (4) .22* 
Gender boy, n (%) 80 (60) 18 (44) 19 (51) .62* 
Outborn, n (%) 54 (40) 13 (32) 9 (24) .063* 
Catheterized¹, n (%) 
       PICC, n (%) 
Mechanical ventilated¹, n (%)  
      ≥7 days, n (%) 
Postnatal steroids, n (%) 
Total parenteral nutrition, n (%) 
      ≥14 days, n (%) 

































Length of stay, median (IQR) 36 (18-72) 54 (32-84) 54 (36-87) .071° 
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Characteristics of the 212 included neonates are displayed per center in Table 1. Pathogen distribution of 
the 35 lab-confirmed sepsis episodes (bloodstream and urine tract infections) are in Table 2.  
Episode classification, incidence, and sampling practice  
Classification of the suspected episodes and indications for sampling stratified per center are displayed in 
Table 3. Among the 299 included samples, 66 (23.1%), 76 (24.7%), and 156 (52.2%) respectively were 
classified as ‘lab-confirmed sepsis’, ‘clinical sepsis’, and ‘no sepsis’.  
The proportion blood cultures sampled in suspicion of HAS per total admissions during the 18-months 
study period was respectively 23.3% (center-1, 192/825), 10.0% (center-2, 60/600), and 6.7% (center-3, 
47/704) (P <.001); incidence of lab-confirmed sepsis was respectively 3.6% (center-1, 30/825), 4.6% 
(center-2, 28/600), and 1.1% (center-3, 8/704) (P <.001). Also, the proportion of lab-confirmed sepsis per 
suspected episodes was significantly different between the 3 centers: 15.6% (center-1, 30/192), 46.6% 
(center-2, 28/60), 17.0% (center-3, 8/47) (P <.001). 
For the total cohort, median number of clinical signs per suspected episodes was significantly lower for 
the cohort ‘no sepsis’ (1, IQR 0-1) compared to ‘lab-confirmed sepsis’ (3, IQR 1-4) (P <.001); in contrast, 
median CRP was not significantly different between these 2 cohorts, 10.0 mg/L (IQR 0.0-22.3) for ‘no 












IQR, interquartile range; °Kruskal-Wallis test; *Fischer’s Exact test. 
 
Antimicrobial therapy 
The proportion ABT of ≥5 days for ‘lab-confirmed sepsis’ and ‘clinical sepsis’ for center-1, -2, and -3 was 
70/146, 46/46, and 26/31 (P <.001) respectively. For center-1, 76 episodes were treated with antibiotics 
for ≥5 days without the presence of at least 2 clinical signs; of these 76 episodes, 54 (71%) had a CRP of 
>10 mg/L. For center-3, 5 episodes were treated with antibiotics for ≥5 days without the presence of at 
least 2 clinical signs of which 4 had a CRP of >10 mg/L.  Of the 248 total episodes treated with antibiotics, 
23 (9%) were inappropriate; no significant difference was found between the 3 centers.  
Model development  
Unadjusted odds of indicators for lab-confirmed sepsis are reported in Table 4. Concerning the clinical 
signs, ‘impaired peripheral perfusion’ and ‘ileus/feeding intolerance’ and concerning the risk factors, 
‘mechanical ventilation’, ‘PICC’, and ‘TPN ≥20 days’ were significantly associated with lab-confirmed 
sepsis; odds of indicators, after adjustment for ‘lethargy’, ‘tachypnea/oxygen need’, ‘apnea/bradycardia’, 
‘VLBW’, ‘surgery’, ‘TPN ≥20 days’, and ‘postnatal steroids’ (model 2), are in Table 5. Another model was 
developed with an ad random combination of 2 clinical signs, after adjustment for ‘VLBW’, ‘surgery’, 
‘TPN ≥20 days’, and ‘postnatal steroids’ (model 1). Predictive performance for ‘lab-confirmed sepsis’ of 
Table 3. Classification of Episodes, Indications for Sampling and Antimicrobial Therapy Administration after Sampling per Center 
Characteristic Center-1 Center-2 Center-3 P Value 
Suspected episodes, n (%) 
     No sepsis   
          Contamination, n (%) 
     Clinical sepsis, n (%) 
     Lab-confirmed sepsis, n (%) 
          Bloodstream infection, n (%) 
          Necrotizing enterocolitis, n (%) 
          Ventilator-associated pneumonia, n (%) 





































Clinical signs, median (IQR) 
     Zero clinical signs, n (%) 
C-reactive protein mg/L, median (IQR) 
     <6 mg/L, n (%) 
     ≤10 mg/L, n (%) 
Antimicrobial therapy initiation, n (%) 































those 2 models and of the NOSEP-score value ≥8 is also represented in Table 5. Model 1 is preferred 
above model 2 because of the broader spectrum; predictive performance for ‘lab-confirmed and/or 
clinical sepsis’ of model 1 and for the NOSEP-score value ≥8 is shown in Table 6. Adjusted for center, 
identical AUC was observed (data not shown).  
Post hoc analysis for a cohort of neonates estimated weighing <1500 g at time of blood culturing (n = 
140) revealed no difference in unadjusted indicators except for ‘PICC’; the latter was contrariwise not 
significantly associated with lab-confirmed sepsis (appendix 4). Visual presentation of the ROC-curve of 
model 1 in all neonates and in a cohort of neonates estimated <1500 g at time of culturing is in Figure 















































Clinical indication Frequency per  
299 episodes (%) 
OR (95% CI) P Value 
Lethargy 65 (21.7) 1.8 (1.0-3.4) .06 
Impaired peripheral perfusion 70 (23.4) 2.5 (1.4-2.6) .002 
Fever 72 (24.1) 1.2 (0.7-2.3) .49 
Tachypnea/oxygen need 112 (37.5) 1.4 (0.8-2.5) .22 
Ileus/feeding intolerance 52 (17.4) 2.5 (1.3-4.7) .007 
Apnea/bradycardia 113 (37.8)  1.1 (0.6-1.9) .76 
Hyperglycemia 25 (8.4) 1.8 (0.7-4.3) .22 
Hypotension 11 (3.7) 0.3 (0.1-2.7) .31 
Oliguria 6 (2.0) 0.7 (0.1-6.1) .75 
Base excess 10 (3.3) 0.9 (0.2-4.2) .87 
2 Clinical signs 152 (50.8) 2.1 (1.2-3.8) .009 
3 Clinical signs 84 (28.1) 2.2 (1.2-3.9) .008 
CRP ≥10 mg/L 134 (44.8) 1.0 (0.6-1.8) .90 
CRP ≥14 mg/L 116 (38.8) 1.1 (0.6-2.0) .69 








Risk factor    
Catheterized >24h 
     PICC 
Mechanical ventilated >24h 
     ≥7 days 
Postnatal steroids 
Surgery 
Total parenteral nutrition 
     ≥14 days 




























Patient-specific risk factor    
Birth weight ≤1500 g 
Gestational-age ≤31 weeks 
Gender, boy  















Table 5. Performance of Sepsis Indication Models and NOSEP-score-8 for ‘lab-confirmed sepsis’ 
aOR, adjusted odds ratio; AUC, area-under-the-receiver-operating-characteristic-curve; CI, confidence interval; NPV, negative-predictive value; PICC, peripherally-inserted central catheter; PPV, 






























Of fit (P) 
2 Clinical signs 2.6 (1.4-4.7) .002 0.67 (0.59-0.74) 74 48 64 81 79 0.615 
Catheterized with PICC >24h 





       
Model 2          
Ileus/feeding intolerance 
Impaired peripheral perfusion 
Catheterized with PICC >24h 









0.66 (0.58-0.74) 53 72 61 81 80 0.657 
NOSEP-score-8   0.56 (0.48-0.64) 52 60 0 100 78  
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Figure 1. Receiver-operating-characteristic-curve (ROC) for ‘lab-confirmed and/or clinical sepsis’             Figure 2. Receiver-operating-characteristic (ROC) curve for ‘lab-confirmed and/or clinical sepsis’ 
in all infants; AUC=0.84.                                                                                                                                in neonates weighing  <1500 gram; AUC=0.81. 
Model 1 aOR  
(95% CI) 













Of fit (P) 
2 Clinical signs 20.4 (11.0-37.9) <.001 0.84 (0.79-0.89) 85 77 77 85 81 .561 
Catheterized with PICC >24h 





       
NOSEP-score-8   0.54 (0.48-0.61) 47 62 53 56 55  
aOR, adjusted odds ratio; AUC, area-under-the-receiver-operating-characteristic-curve; CI, confidence interval; NPV, negative-predictive value; PICC, peripherally-inserted central catheter; PPV, positive-




We described sampling practice in suspicion of HAS per center; substantial differences between the 
centers were observed. Additionally, (un)adjusted odds of indicators for ‘lab-confirmed sepsis’ were 
reported. The developed sepsis indication model had weak predictive performance for ‘lab-confirmed 
sepsis’ and good predictive performance for ‘lab-confirmed and/or clinical sepsis’.   
Incidence and sampling practice 
Difference in incidence of HAS between center-1 or -2  and center-3 indicates a case mix in population. 
The proportion of samples per total admissions is substantially lower in center-2 though incidence of 
HAS is similar to center-1; NOSEP-score value ≥8 as a threshold for sampling in center-2 might be 
responsible for this. To our knowledge, research on blood culture sampling frequencies in neonates is 
limited. Blackburn et al.153 reported a 48% proportion samples per admissions in a tertiary neonatal unit 
in London at day of birth of which 15% were lab-confirmed on day 8.  
For center-1, a proportion of 27% zero clinical signs per suspected episode, a median of 1 clinical sign, 
and a median CRP level of 11 mg/L at time of blood culturing might indicate a sampling practice based on 
CRP level or probably other biomarkers or risk factors. Contrariwise for the other 2 centers, sampling 
practice for HAS is more driven by clinical signs (median of 3 clinical signs) and not by CRP level. Similar 
to center-2 and -3, are the results of the proportion normal CRP (≤10 mg/L) in the study of Bekhof et 
al.122; in this study, more than half of the suspected HAS cohort (65%) had normal CRP. This result is in 
contrast to the results of Ohlin et al.140 conducted on 401 neonates with suspected bloodstream 
infection; they found that only 22% (90/401) had a CRP value below 10mg/L.   
Remarkable are the results for center-2: an efficient sampling practice is observed guided by the NOSEP-
score and since we found a median of 3 clinical signs at time of culturing, the clinical condition is also 






Because of the possible devastating consequences of HAS, a low threshold for initiating antimicrobial 
therapy is generally accepted which is also observed in center-1.47 Nonetheless, inadequate, 
inappropriate, or unnecessary empiric treatment can foster antimicrobial resistance, compromise 
gastrointestinal immunity and be associated with adverse outcomes.48, 50 Antimicrobial stewardship 
programs can be helpful to reduce antimicrobial initiation and duration in NICU.49, 52, 98, 159  
Model development 
As the median number of clinical signs is significantly higher in the ‘lab-confirmed sepsis’ cohort 
compared to the ‘no sepsis’ cohort, and the occurrence of 2 or 3 ad random clinical signs at time of 
culturing have higher odds for ‘lab-confirmed sepsis’, the presence of several clinical signs can be 
valuable as sepsis indicator, as also shown in adjusted regression analysis. In contrast, unadjusted 
regression analysis confirms that most clinical signs are in separation no specific sepsis indicators; only 
‘ileus/feeding intolerance’ and ‘impaired peripheral perfusion’ appear to be specific symptoms for lab-
confirmed sepsis. Since heterogeneity in symptom definition and population is observed, comparison 
with other research results is difficult. Bekhof et al.122 included solely infants <34 weeks of gestational 
age to identify clinical signs of lab-confirmed sepsis and found that ‘increased respiratory support’, 
‘capillary refill >2s’, and ‘grey skin’ were associated. In the study of Ohlin and colleagues140, association of 
clinical signs with lab-confirmed sepsis (late- and early-onset) was adjusted for sex and gestational age 
(<37 week versus ≥37 weeks); they discovered that for low gestational age infants ‘apnea’, ‘bradycardia’, 
‘impaired peripheral circulation/hypotension’, ‘feeding intolerance’, and ‘distended abdomen’ were 
significantly associated. Modi et al.56 searched for a clinical signs associated with lab-confirmed sepsis in 
low gestational age infants (≤31 weeks) and found that all 10 signs as applied in our study were 
significantly associated. Although the same definitions of the signs were used, comparison with Modi et 
al.56 is probably inappropriate since they included all NICU patients rather than neonates with suspicion 
of HAS.  
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We did not find an association between ‘CRP-rise’ and ‘lab-confirmed sepsis’ which is in contrast to the 
study results of Ohlin et al.140 and Mahieu et al.120 but in agreement with other studies. 56, 160 The 
predictive value of CRP is controversial since an increase in CRP is known as a late diagnostic marker for 
infection.45, 160, 161 Mechanical ventilation and central line catheterization are well known risk factors for 
HAS and frequently included in prediction models.8, 35, 100, 122, 124 
Prediction of HAS is a major issue in NICUs. Unspecific signs and case mix in NICU population hamper 
development of accurate prediction models; as for NOSEP-score value ≥8, though perceived with 
moderate diagnostic accuracy158 and externally validated with good AUC after redefining cut-off of 
NOSEP-items121,  external validation in our cohort was not good. For this, we focused on the 
development of an indication model with clinical signs guiding blood culture sampling by recognition of a 
broad spectrum of neonates at risk for HAS. Subsequently, the predictive performance of our model for 
‘lab-confirmed and/or clinical sepsis’ as outcome is of superior importance also keeping in mind the 
imprecise blood culture test. In addition, it is our belief that clinically ill neonates cannot be left without 
initiation of diagnostic procedures and treatment. However, defining a clinically ill neonate is essential 
and might lead to appropriate culturing. Our results confirm the value of the occurrence of ‘2 ad random 
clinical signs’ for defining ‘clinical sepsis’.   
Limitations and recommendations 
It is possible that some infants might be wrongly classified since blood culture test is imprecise. However, 
our applied definition of lab-confirmed sepsis caused by skin commensals with additional criteria most 
probably exclude the false-positive cultures.   
In clinical practice, the interpretation of the nonspecific clinical signs is not always obvious and probably 
facing interobserver variability which might have influenced our results. However, for most clinical signs 
standardized definitions were used. Also, limited incidence of some clinical signs might have introduced 
bias (Type-I-error) in unadjusted analysis; however, since our indication model includes the occurrence 
of ‘2 ad random clinical signs’, all signs are considered equally important.  
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When a larger cohort is obtained, future research can explore the integrated value of sepsis-related 
biomarkers and of ‘heart rate instability’ since recent results on predictive value for HAS seems 
promising.131, 137, 146, 148, 152, 157 It also can be recommended to adapt the sepsis indication model towards 
center-specific services which might implicate center-specific risk factors. For this, the model should be 
validated in larger multicenter cohorts. Besides validation of the model, a future randomized controlled 
trial might focus on mortality and economic impact of model implementation. Less blood culture 
samples results in less workload for the staff, a financial profit for the hospital and can result in 
decreased antimicrobial therapy initiation.98, 162 Moreover, we cannot ignore the decreased burden for 
the neonate.  
CONCLUSION  
Center heterogeneity in sampling practice is substantial. Although not obvious to uniform due to case 
mix in population, sampling practice can be optimized by using the NOSEP-score additionally to the 
presence of clinical signs. The predictive performance of our indication model for ‘lab-confirmed and/or 
clinical sepsis’ should be validated in a larger cohort and a randomized controlled trial can explore the 
impact of its implementation. 
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Date: STICKER LABEL 
 Puncture site: 
 Skin 
 Catheter 
 Blood volume: 
 1mL aerobe  
   other:…………mL 
 0,5mL anaerobe   
   other:…………mL  
 
   CRP-value:………..mg/L 
 
  Prior antibiotics: yes / no 
  
 Antibiotic initiation: 
yes/no 
Clinical signs leading to culturing: 
 Tachypnea or clinical relevant ↑O2/ventilation 
 Clinical relevant ↑apnea/bradycardia episodes 
 Hypotension:  >1500g (<40mmHg Sys) 
                                                          < 1500g (<35mmHg Sys + oliguria) 
 Glucose intol. (2 subsequent values >150mg/dL) 
 Poor peripheral perfusion: cap. refill >3sec.; 
pallor/ mottling/peripheral T° gap >2°C 
 Lethargy/ irritability 
 T° instability (<36° C or >38°C) 
 Ileus / feeding intolerance (>10% residue) 
 Oliguria (<1mL/kg/h last 12h) 
 Base excess (< -10mmol/L) 
 Other signs: …………………………………………………….. 














Appendix 2  
PROCEDURE FOR BLOOD CULTURING 
 
1. Wash hands, dry hands, disinfection with alcohol. Wait till hands are dry 
 
2. Disinfection of bottles with alcohol-swab for at least 30 seconds; wait till hubs are dry (at least 30 seconds) 
 
   
 
3. Disinfection of puncture site with alcohol-swab (skin or catheter-hub) for 30 seconds; wait till 




4. Do not palpate the puncture site; in case of arterial skin puncture, palpation is allowed on distance 
 




6. Aspirate at least 1,5ml blood  
 
7. Inject 1mL blood in the green (aerobe) bottle; 0,5mL in the red (anaerobe) bottle. Other quantities can be 







 Registration of every new episodes; at least 8 days between first and second  episode 
 *TTP: Time to Positivity  
 ** Catheter/MV-days: days at time of blood culturing  
 *** Recent surgery: max 7 days between surgery and blood culturing  
 BSI: bloodstream infection;  
 
Diagnostic Item Value Cut-off Score 
CRP  …. mg/dL > 1,3 mg/dL 5 
Neutrophil fraction …. % > 50% 3 
Thrombocytes ……… / mm³ < 150.000/mm³ 5 
Fever …, . . °C > 38.2 °C 5 
TPN  ……. days > 13 days 6 





MODI MODEL 10 CLINICAL SIGNS and CRP  
 Blood volume 1e collection 
 1mL aerobe 
 other:…………………mL 





 Blood volume 2e collection 
 1mL aerobe 
 other:…………………mL  




Clinical signs leading to blood culturing 
J / N Tachypnea or clinical  relevant ↑O2- of ventilation need 
J / N Clinical relevant ↑ apnea/bradycardia episodes 
J / N Hypotension:  >1500g (<40mmHg Systolic) 
                                                          < 1500g (<35mmHg Systolic + oliguria) 
J / N Glucose intolerance (2 subsequent values of  >150mg/dL) 
J / N Poor peripheral perfusion: capillary refill >3sec./ pallor / 
mottling/peripheral T° gap >2°C 
J / N  Lethargy/  irritable 
J / N T° instability (<36° of >38°) 
J / N Ileus / feeding intolerance (>10% residue) 
J / N Oliguria (<1mL/kg/h last 12h) 
J / N Base excess  (< -10mmol/l) 
 
OTHER SIGNS: ………………………………………………………………………………… 
 




   
  CRP-value:……………....mg/dL 
  TTP*:…………………………………… 
  Prior antibiotics: yes / no 
  Days  antibiotics:…………….. 
 
 
Admission date:……………………………date of transfer or death:…….………….. 
Outborn / Inborn / Intra-uterine transfer 
Gender: boy / girl 
BW:…………………………………GA:……………………………… 
Catheter: no / peripheral / arterial / PICC / CVC / umbilical 
Catheter days**:…………………………………………. 
Incubator: open / closed / not applicable 
Mechanical ventilation (MV): yes / no  
Days MV**:……………………………………………….. 
Recent surgery***: yes / no 
Comorbidities: VAP/ NEC / phototherapy / steroid therapy  
Cause of death: BSI / multi-causal / other cause /  not applicable 
Datum:  














Unadjusted Odds of Clinical Indications and Risk Factors for Lab-Confirmed Sepsis in Neonates Weighing  
≤1500 g at time of Episode 
Clinical indication Frequency per  
299 episodes (%) 
OR (95% CI) P 
Lethargy 33 (23.6) 0.9 (0.3-2.1) .75 
Impaired peripheral perfusion 39 (27.9) 2.7 (1.2-5.9) .02 
Fever 33 (23.6) 1.6 (0.7-3.6) .31 
Tachypnea/oxygen need 67 (47.9) 1.4 (0.7-2.9) .38 
Ileus/feeding intolerance 26 (18.6) 2.0 (0.8-4.0) .12 
Apnea/bradycardia 81 (57.9)  1.1 (0.5-2.3) .82 
Hyperglycemia 22 (15.7) 1.4 (0.5-3.7) .53 
Hypotension 10 (7.1) 0.3 (0.1-2.4) .25 
Oliguria 5 (3.6) 0.7 (0.1-6.4) .74 
Base excess 9 (6.4) 0.8 (0.2-4.0) .77 
2 Clinical signs 94 (67.1) 3.3 (1.3-8.6) .012 
3 Clinical signs 64 (45.7) 1.8 (0.9-3.9) .10 
CRP ≥10 mg/L 51 (36.4) 0.9 (0.4-2.0) .85 
CRP ≥14 mg/L 38 (27.1) 1.2 (0.5-2.7) .68 








Risk factor    
Catheterized >24h 
     PICC 
Mechanical ventilated >24h 
     ≥7 days 
Postnatal steroids 
Surgery 
Total parenteral nutrition 
     ≥14 days 
































This epidemiological research aimed for gaining insight in the burden of HABSI retrospectively with a 
prospective validation. Throughout this research, the problem of HABSI incidence, prevention, definition, 
early identification, diagnosis, and treatment in the NICU of Ghent University Hospital has become more 
clear and will be discussed. Now the burden of HABSI is mapped recommendations can be made for (1) 
monitoring current prevention initiatives for compliance, (2) tailoring prevention initiatives towards 
more appropriate and feasible, and (3) standardizing indications for blood culturing and antimicrobial 
therapy initiation. 
Although it is well-known that most HABSIs are evitable and infection prevention initiatives can decrease 
HABSI rates, implementation of such separate implemented initiatives (ie. hand hygiene promotion and 
a protocol for catheter care in 2006) did not reduce HABSI rates in the NICU of Ghent University Hospital 
during the retrospective study period (1992-2011). An important note herein is the very fluctuating CoNS 
HABSI rates and the tremendous reduction of CoNS HABSI incidence in 1994. In 1994, a randomized 
controlled trial on catheter care conducted in our NICU, definitely demonstrated that HABSI is 
preventable; most probably because of compliance to the study protocol and consciousness of research 
participation, reduction of HABSI was observed.  
Before the start of the prospective research, a protocol was implemented on blood culture sampling 
technique (ie. disinfection time and procedure) and catheters with an open system were replaced by a 
closed system. Despite these initiatives, only a marginally reduction in HABSI rate (defined according to 
NICHD criteria and including definite and possible HABSIs) was observed between the retrospective and 
prospective cohort (6.9% versus 5.3%, p=0.08). Considering CoNS HABSIs, the prospective research did 
confirm the high incidence rates (62.2% and 54.5% for the first and last 10-year study period versus 
56.3% for the 18-months prospective study period respectively). A first pertinent question herein is the 
level of compliance to the implemented prevention initiatives? Recalling the results of the RCT in 1994, 
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we might assume that there was no strict adherence to the protocol for blood culture sampling 
technique. This assumption can lead to another pertinent question: why noncompliance? Where the 
prevention initiatives not clearly defined?  Was it the absence of an official protocol registration 
document? Is the level of up-to-date knowledge of the care practitioners concerning prevention and 
burden of HABSI low?  It is obvious that up-to-date knowledge is a condition sine qua non to reach 
optimal quality of care so consequently knowledge gaps can jeopardize compliance to implemented 
prevention initiatives. Although we did not measure the knowledge level of the care staff concerning 
infection prevention, we do recommend continuous education on infection prevention in general and on 
HABSI in particular, because it is acknowledged as an important evidence-based prevention strategy.30, 31, 
163, 164 To achieve continuous education on a ward, e-learning has been proposed in literature as an 
efficient tool. For this, meetings are started up with the educational team of Ghent University Hospital 
and with the neonatologists for discussing the feasibility of the development of a department-specific e-
learning module on infection prevention. In addition to educational strategies, monitoring compliance of 
the already implemented strategies is absolutely warranted. For this, protocol registration forms can be 
helpful. Also,  qualitative research (ie, semi-structured interviews of the different care providers) can 
help to gain insight in which strategies are respected and why strategies are not respected; this 
information is very important to improve feasibility and efficiency and may lead to the development and 
implementation of new department-specific prevention initiatives.  
Furthermore, an interesting comparison is the impact of CoNS HABSI definition on incidence rates. 
Distinction between true infection and contamination when the causative pathogen is a skin commensal, 
is an absolute challenge and a HABSI caused by a CoNS should always raise suspicion of contamination. 
For this, extra criteria are needed and generally accepted in defining CoNS HABSI.1, 10, 56 Since it is 
acknowledged that NICHD criteria may overestimate incidence of CoNS HABSI, we used the more 
vigorous NEO-KISS criteria26 in our prospective research for comparison. The difference in result is 
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remarkable: 3 first-pathogen CoNS HABSIs on 18 first-episode HABSIs defined according to NEO-KISS 
criteria (17%) compared to 22 on 43 first-episodes (51%) defined according to the NICHD criteria 
(p=0.012). Unfortunately the NEO-KISS criteria could not be applied for the retrospective research but 
we may assume that approximately the same difference would have been found. As such, impact of 
HABSI definition is tremendous and compromising benchmarking. As we stated earlier, the absence of 
mortality in the ‘possible HABSI’ cohort is an argument in favor of a preponderance of contamination 
over true infection and confirming the acknowledged overestimation.  
Our prospective multicenter study described numbers regarding identification, diagnosis, and treatment 
of suspected HABSI infants. For identification and treatment, the results of our NICU point out that blood 
culturing practice is less accurate compared to the other 2 participating centers. In our center, blood 
culture sampling frequency is high and sampling is mostly not guided by clinical signs. In general, clinical 
presentation of sepsis varies considerably so identification of infants at risk is challenging. To improve 
posttest probability, implementation of standards or guidelines can be important but unfortunately such 
guidelines do not exist for the detection and treatment of infants in suspicion of HAS. Question is: are 
guidelines feasible and appropriate for clinical practice considering the case mix in population and 
variability in clinical presentation? The use of sepsis prediction scores (for example the NOSEP-score) 
might be a good alternative to improve diagnostic accuracy.98, 162 To strive for accurate sampling should 
be a priority in neonatal intensive care considering the high cost of sampling, the burden for the 
neonate, the workload for the staff, and the negative consequences of inappropriate antimicrobial 
therapy initiation. All these undesirable consequences should raise multidisciplinary awareness and 
subsequently introduce a multidisciplinary approach for quality improvement in sampling practice. 
Therefore, to achieve an optimized sampling practice, a multidisciplinary perception is required: nurses 
and neonatologists can be complementary for the early detection of a suspected infant and the 
determination of sampling and antimicrobial therapy initiation. Nurses are very important because of 
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their observational skills, neonatologists are important because of their medical knowledge and both 
care providers may better attune their communication skills.  
Some limitations need to be considered which are inherent to the imprecise diagnostic test for HABSI 
and intrinsic for a retrospective study. Our retrospective data might be prone to information bias due to 
data gaps and misclassification of the HABSI episodes. Data gaps were statistically corrected and 
misclassification was taking into account when interpreting our results. Also for the prospective research 
misclassification might be an issue, though the more rigorous criteria for lab-confirmed CoNS HABSI most 
probably distinguish correctly true CoNS HABSI versus contamination. Another limitation of the 
prospective study, is the probable interobserver variability of the clinical signs. Interpretation of some 
clinical signs is difficult to standardize but it is our believe that terming the signs as ‘acute onset of’ or 
‘increase need for’ is a standardized method to define the clinical eye of the neonatologist or nurse. A 
major strength of the retrospective study is the large historical cohort, the additional review of all 
medical files of HABSI cases (definite, possible, and probable) by the principal investigator, and the use of 
the NICAUDIT computer system which applies standardized definitions for all included variables. A major 
strength of the prospective study is the multicenter approach increasing the power.  
Recommendations can be made for clinical practice based upon the outcome of this epidemiological 
research. First, monitoring compliance may focus on adherence to hand hygiene, proper blood culture 
sampling, catheter care protocol, and correct catheter insertion technique; these prevention initiatives 
can be bundled in one infection prevention protocol and defined as a fundamental care bundle because 
of the high incidence of CoNS HABSI and short time to infection in our NICU. Second, besides monitoring 
compliance, continuous education on infection prevention in general and on HABSI in particular is 
warranted. Furthermore, it can be recommended to form a multidisciplinary sepsis team including a 
nurse specialist and a neonatologist, that actively participates in an (inter)national surveillance program 
so more consciousness for healthcare-associated sepsis can be attained. Also, this multidisciplinary 
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sepsis team could implement a sepsis indication/prediction model in identification of patients at risk in 
order to increase diagnostic accuracy and decrease inappropriate antimicrobial therapy initiation. We 
note that it might be beneficial to focus on multidisciplinary approaches during nursing and medical 
schooling; additionally, training of communication skills can also be emphasized. Finally, it is also 
recommended to validate the current developed sepsis indication model in a new cohort and optimize it 
by adding additional easy-to-use bedside markers. For validation in subsequent research, more power is 
warranted so stratified sepsis indication models can be developed; stratification by actual weight and 
center-specific risk groups might result in more appropriate identification and more accurate prediction 
of HAS.  
In conclusion, department-specific epidemiological research is important to discover particular patterns 
and risk factors. These insights can optimize quality of care concerning HAS prevention, identification, 
diagnosis, and treatment. Awareness of the burden of HAS is fundamental and although diagnosis of HAS 
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